The current landscape of therapeutic vaccination approaches for treatment of HPV-dependent malignancies Authors: Johanne Audouze-Chaud, Ann-Katrin Schlosser, Angelika B. Riemer Published: 2026 ABSTRACT This review provides an overview of current therapeutic human papillomavirus (HPV) vaccination approaches. We review important criteria for their development, and present vaccines currently being actively followed in clinical trials, for precursor lesions or established cancers. Subsequently, we list approaches that reached clinical trial stage but were abandoned. Lastly, we discuss promising preclinical studies. We conclude with a brief overview of novel in silico tools developed to enhance vaccine design. Introduction Human papillomaviruses and cancer Human papillomaviruses (HPV) comprise over 200 known double-stranded DNA viruses infecting basal keratinocytes of squamous epithelia of the skin and mucosae. Although most HPV types cause no disease or only benign skin and anogenital warts, at least 12 HPV types have been described as oncogenic and termed high-risk types (hrHPV). These include HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 (https://monographs.iarc.who.int/list-of-classifications). Of note, the low-risk types HPV6 and HPV11 are associated with the development of recurrent respiratory papillomatosis (RRP)1. In most cases, HPV infections, even high-risk infections, resolve spontaneously within two years, attesting for HPV susceptibility to immune attack. This has also recently been showcased by the first FDA approval of a therapeutic HPV vaccine, which targets the low-risk types HPV6 and HPV11 in the context of RRP (https://www.fda.gov/news-events/press-announcements/fda-approves-first-immunotherapy-recurrent-respiratory-papillomatosis). Persistent infections with high-risk HPV types are a necessary prerequisite for the development of multiple malignancies, including cervical, other anogenital as well as a subset of head and neck cancers (mainly oropharyngeal), overall accounting for 5% of all cancer cases worldwide, i.e. about 730,000 cases in 20222. HPV16 is the most prevalent hrHPV and is responsible for ~60% of cervical cancers and over 85% of HPV-induced head and neck cancers3,4. HPV18 ranges second, causing ~15% of cervical cancer cases3,5. Before reaching the stage of advanced cancer, hrHPV are responsible for the development of precursor lesions, so-called intraepithelial neoplasia (e.g. CIN—cervical intraepithelial neoplasia), which are even more prevalent. As an example, in Germany, it is estimated that 6250 women are diagnosed with HPV-related cancers each year, while about 56,000 women are treated for precursor lesions within the same timeframe (https://www.rki.de/DE/Aktuelles/Publikationen/RKI-Ratgeber/Ratgeber/Ratgeber_HPV.html). Prevention, detection and treatment of HPV-related cancers It is estimated that virtually all sexually active individuals will be exposed to HPV in the course of their life6. Prophylactic vaccines are based on viral-like particles (VLPs) consisting of the type-specific capsid protein L1 and protect individuals who have not yet been in contact with the targeted HPV types, from future infections with those HPV types, mainly by inducing neutralizing antibodies. Prophylactic HPV vaccines (e.g. GardasilTM, CervarixTM or CecolinTM) have been introduced in the national immunization program of 125 countries for girls, while 47 countries introduced them for boys as well7,8. However, only 28% of girls had received their first dose of HPV prophylactic vaccine in 2023 (https://www.who.int/data/gho/data/indicators/indicator-details/GHO/girls-aged-15-years-old-that-received-the-recommended-doses-of-hpv-vaccine), a number far below the objective of 90% global coverage to be reached by 2030, defined in the WHO strategy to accelerate the eradication of cervical cancer7. While effective in individuals naïve to HPV, prophylactic vaccines do not protect from the development of lesions in individuals that are already infected by hrHPV. Regular screenings with Papanicolaou (Pap) smears as well as HPV-DNA testing allow early detection of HPV infections in the cervical region. Similar screenings are performed in the anal region on high-risk individuals, such as HIV+ men having sex with men9,10. However, to date, there is no effective oropharyngeal cancer screening program available, due to the poor sensitivity of the available screening techniques for head and neck HPV infections11. The current standard of care for detected lesions is dependent on their stage and location. Cervical precursor lesions are typically treated by conization or ablative treatments, which incur future childbearing risks. Other precursor lesions are typically ablated. When detected at an early stage, precursor lesions are not treated right away, but regularly monitored in the hope of a spontaneous regression, leading to strong psychological burden of the patients. Early cervical cancer is primarily treated by surgery or by radiotherapy with concurrent chemotherapy at later stages of the disease. Advanced cervical cancers are typically treated with platinum-based chemotherapy and radiotherapy9. The first line of treatment for oropharyngeal cancer consists of surgery and/or definitive radiotherapy at an early stage, while advanced stages are treated with platinum-based chemotherapy or resection followed by adjuvant radiotherapy12. Treatment options are the same regardless of HPV status, although HPV-positive head and neck cancers are associated with a better prognosis13. Therefore, de-escalation treatments for HPV-positive oropharyngeal carcinoma are currently being explored14. Immune checkpoint blockade has additionally been tested in HPV-positive cervical and oropharyngeal cancers, and, albeit limited efficacy, is now part of the treatment guidelines15,16. The severe side effects associated with surgery, radiotherapy, and chemotherapy, together with the limited efficiency of immune checkpoint blockade, stress the need for novel treatment options. Therapeutic vaccination, representing a non-invasive approach with the promise of high specificity and low side effects, is an attractive alternative to existing treatments and is therefore actively researched. Unlike prophylactic vaccination, therapeutic vaccines aim at the induction of antigen-specific cytotoxic T lymphocytes (CTLs) that kill and thus eliminate infected or transformed target cells. As advanced HPV-induced lesions actively suppress local immunity, it would be especially interesting to introduce therapeutic HPV vaccination as a treatment for precursor lesions such as cervical intraepithelial neoplasia (CIN), vulvar or vaginal intraepithelial neoplasia (VIN, VaIN), penile intraepithelial neoplasia (PIN), or anal or peri-anal intraepithelial neoplasia (AIN, PAIN). Indeed, the WHO recently published preferred product characteristics (PPC) for therapeutic HPV vaccines targeting CIN17. It is worth noting that therapeutic HPV vaccination in this scenario can take advantage of a long therapeutic window, since an intraepithelial lesion generally takes over a decade (in average 15 years) to develop into cancer (https://www.who.int/news-room/fact-sheets/detail/human-papilloma-virus-and-cancer). Specific HPV proteins as targets for therapeutic HPV vaccines As the vast majority of HPV-driven cancers arise from HPV16 and HPV183–5, most HPV therapeutic vaccination approaches have focused on these two HPV types. In rare cases, other high-risk types were also included. HPV encodes early (E) and late (L) genes. The proteins derived from the early genes (E1, E2, E4, E5, E6, and E7) are important for completing the viral life cycle, while the late gene products (L1, L2) are the structural proteins forming the viral capsid. All currently approved prophylactic vaccines target the L1 protein and induce virus-neutralizing antibodies. However, the late genes are not expressed in HPV-transformed cells and can therefore not represent targets for therapeutic vaccination18. This explains why prophylactic vaccines, which target the L1 protein, cannot exhibit any therapeutic effect. E6 and E7, termed “oncoproteins”, maintain an active cell cycle in the host cells—a prerequisite for viral replication, and a feature that is typically no longer present in suprabasal keratinocytes. E7 binds to the cellular checkpoint pRb, breaking its interaction with the transcription factor E2F, which causes the transcription of several proteins, including cyclin E, cyclin A, and p16INK4A, and a subsequent premature entry of the cells into the S phase. Meanwhile, E6 binds the cellular ubiquitin ligase E6AP and the tumor suppressor molecule p53, promoting its rapid ubiquitination and degradation via proteasomes. This results in the prevention of cell cycle arrest and apoptosis, thereby allowing uncontrolled cell proliferation. Besides, E6 and E7 have been shown to mediate interferon signaling suppression19 and can alter c-myc expression, leading to further cell cycle dysregulation through abnormal cyclin and downstream transcription factor expression. Together, E6 and E7 induce abnormal and uncontrolled cell proliferation, contributing to the shift of the cell to a malignant state20. However, further genetic hits are required for malignant transformation, which are acquired over time in HPV-immortalized cells due to increasing genetic instability21. As E6 and E7 expression is crucial for the viral life cycle, it is maintained throughout disease stages, from infection to advanced cancer22. No escape mutants can arise that would not express E6 or E7, as HPV-driven malignancies are dependent on their sustained expression23. Therefore, E6- and E7-derived epitopes are presented at the surface of all HPV-infected malignant cells, rendering them ideal targets for therapeutic vaccination20. Furthermore, viral proteins are immunologically foreign, therefore no central tolerance against them exists in the host, and immune responses elicited against them do not lead to potential autoimmunity. This allows a clear targeting of tumor cells in the context of therapeutic HPV vaccination. Other early HPV proteins, such as E2 and E5, have also been considered as targets for therapeutic HPV vaccination24, but they are not expressed in all disease stages. For instance, E2 is typically lost upon viral genome integration21. E1-derived antigens were also found to be immunogenic in cervical cancer patients25, although those were discovered and explored more recently. Therefore, most therapeutic HPV vaccines use E6 and E7 as target antigens26,27. To achieve this, it is of utmost importance that these epitopes are actually being MHC-presented at the surface of HPV-infected/transformed cells and can be recognized by T cells28. An example of such a peptide is HPV16 E711-19, which was detected in a conserved manner at the surface of HPV16-infected cells by mass spectrometry, induced specific T cell-mediated killing29, and was successfully translated to effective clinical immunotherapy in the context of a transgenic T cell receptor (TCR) T cell product30. Considerations for the development of HPV therapeutic vaccines Therapeutic HPV vaccines have been developed on various platforms, which have been reviewed elsewhere26,31,32. Briefly, live-vector vaccines such as bacterial or viral vectors are highly immunogenic, but can be associated with higher toxicities and immune responses targeting the vector instead of the delivered antigen. DNA vaccines are easy to produce and well tolerated, but generally display less immunogenicity due to less efficient delivery approaches. RNA-based vaccines offer the advantage of being easily delivered to the cells, but special caution must be taken to avoid their degradation during manufacturing and transport. Peptide- and protein-based vaccines are stable and safe, and thus good antigen sources. However, they do not possess the inherent adjuvanticity of live-vector or nucleic acid-based vaccines, and therefore need to be combined with adjuvants. In the case of short peptide-based vaccines, they also require to be tailored to the patients’ HLA repertoire and be delivered in a way that ensures targeting to APCs. Finally, dendritic cell vaccines are highly immunogenic and stimulate both the innate and adaptive immune response. However, the manufacturing process is difficult and costly, making it challenging for higher scale purposes. Another important consideration is the stage of cancer development at which a therapeutic vaccine intervention is being conducted. At the first stages of HPV infection (persistent infection, CIN1 in the cervix), the immune system is considered “ignorant”, as the virus employs mechanisms to evade innate immunity and delay the activation of an adaptive immune response33,34. These include, among others, low viral gene expression, as well as the alteration of protein functions and immune cell interactions21,35,36, and downregulation of MHCI and II expression37,38. At this stage, E2 is still expressed and represses E6 and E7 expression, and HPV remains mostly episomal. As the infection progresses, the tumor immune micro-environment switches from an ignorant to an immunocompromised state. As the HPV genome integrates into the host cell, the E2 gene is disrupted, allowing E6 and E7 to be overexpressed. The infected cells undergo immortalization, and an immunosuppressive environment settles: Tregs infiltrate the lesion site and proinflammatory cytokines and chemokines are repressed, while regulatory cytokines such as TGF-β are upregulated33,34. While specific T-cell mediated killing failed to be induced in the immune ignorance phase, the effector mechanisms of specific T cells are actively repressed in the immunocompromised state. For this reason, therapeutic vaccines administered alone should target precursor lesions (i.e. early stage intraepithelial neoplasia) to overcome immune ignorance. This approach, termed “cancer interception”, allows to eliminate the lesion before it develops into cancer, positioning itself between classical prophylaxis, or primary prevention, and treatment, or secondary prevention. If therapeutic vaccines are employed in advanced and thus immunocompromised cancer lesions, they need to be used as part of a combined treatment that also tackles the immunosuppressive milieu. Therefore, we discriminated in this review between therapeutic vaccines targeting precursor lesions versus vaccines targeting cancers. We searched the relevant databases (PubMed, ClinicalTrials.gov) for therapeutic HPV vaccines tested in the clinic, to provide an up-to-date overview of approaches currently being pursued. Search terms included “HPV”, “therapeutic vaccine”, “therapeutic vaccination”, “therapeutic HPV vaccine”, “therapeutic HPV vaccination”. We additionally searched both databases with the names of the vaccines previously found to gain a complete overview of all the trials, including each vaccine. Additional information sources (conference reports, company press releases, and websites) were also included in the search. We included a section about therapeutic HPV vaccines that have reached the clinical stage but are not actively followed anymore. Next, we highlight a selection of promising vaccines tested at the preclinical stage, and give an outlook on in silico tools currently employed for vaccine design. Finally, we summarize recent advancements and discuss the major areas of improvement in the development of therapeutic HPV vaccines. Therapeutic HPV vaccines that are actively clinically investigated Numerous vaccines have entered clinical trials in the last two decades. These include DNA, mRNA, whole protein, peptide, as well as viral and bacterial vector-based vaccines. An overview of currently clinically investigated vaccines, their target proteins and delivery systems, their developers, indication, and clinical trial phase reached is given in Table 1. While some vaccines have been tested in both precursor lesions and advanced cancers, others were assessed for only one disease state. As the lesion stage is an important parameter for therapeutic vaccine indication, we separated vaccines tested in precursor lesions from the ones tested in advanced cancers.Table 1Therapeutic HPV vaccines actively followed in clinical trials for either precursor lesions or cancer, sorted by vaccine type and highest clinical phase reachedVaccine nameVaccine typeDeveloperVaccine compositionIndicationHighest clinical phaseHPV type and protein/peptide targetedDelivery system/adjuvanted byVGX-3100DNAInovio Pharmaceuticals / ApolloBioHPV16 E6/E7 & HPV18 E6/E7Precursor lesionsIIIINO-3112/MEDI0457DNAInovio PharmaceuticalsHPV16 E6/E7 & HPV18 E6/E7INO-9012 (DNA vector encoding IL-12)CancerIIpNGVL4a “family”DNAJohns Hopkins/PapivaxpNGVL4a-Sig/E7(detox)/HSP70 & pNGVL4a-CRT/E7(detox): HPV16 E7pNGVL4a-CRTE6E7L2 (PVX-4): HPV16 E6/E7/L2pBI-11 (PVX-8): HPV16 E6/E7 & HPV18 E6/E7 + Hsp70Hsp70 or calreticulinPrecursor lesions & cancerIIIIGX-188EDNAGenexineHPV16 E6/E7 & HPV18 E6/E7Flt3L + GX-I7(long-acting IL-7)CancerIIVB10.16DNANykodeHPV16 E6/E7CCL3L1CancerIINWRD08DNANewish TechnologyHPV16 E6/E7 & HPV18 E6/E7-Precursor lesionsIBNT113mRNABioNTechHPV16 E6/E7Lipoplex particlesCancerII/IIIRG002mRNARinuaGene BiotechHPV16/18 E2/E6/E7Lipid nanoparticlesPrecursor lesionsI/IICD40HVacProteinEnnoDCHPV16 E6/E7Anti-CD40 mAb, poly-ICLCCancerI/IITA-CINaProteinJohns Hopkins/PapivaxHPV16 E6/E7/L2-CancerIPDS0101Synthetic long peptidesPDS Biotech6 HPV16 E6/E7 synthetic long peptides (SLPs)Cationic lipid nanoparticlesCancerIIIISA101/101bSynthetic long peptidesISA Pharmaceuticals (currently ISAbella Pharma)13 (for ISA101) or 12 (for ISA101b) HPV16 E6/E7 overlapping SLPs: E61-32, E619-50, E641-65, E655-80, E671-95, E685-109, E691-122, E6109-140, E6127-158, E71-35, E722-56, E743-77 (only in ISA101), E764-98MontanideCancerIIPepCanSynthetic long peptidesUniv. of Arkansas4 HPV16 E6 SLPs: E61-45, E646-80, E681-115, E6116-158Candida albicans skin test reagentCancerI/IICUE-101Short peptideCue BiopharmaHPV16 E711-20, HLA-A2-restrictedFusion protein of HLA-A2, HPV16 E711-20, IL-2, and IgG1 Fc domainCancerIIPRGN-2009Viral vectorPrecigen35 non-HLA-restricted CTL epitopes of HPV16 E5/E6/E7 & HPV18 E6/E7GC46 gorilla adenovirusCancerIIVvax001Viral vectorViciniVaxHPV16 E6/E7Semliki Forest virus repliconPrecursor lesionsIITA-HPVaViral vectorJohns Hopkins/PapivaxHPV16 E6/E7 & HPV18 E6/E7Vaccinia virusPrecursor lesions & cancerIIITG4001Viral vectorTransgeneHPV16 E6/E7Modified Vaccinia Ankara virus (MVA); IL-2CancerI/IIIGMKK16E7Bacterial vectorNihon Univ., TokyoHPV16 E7Lactobacillus paracaseiPrecursor lesionsI/IIHsp70 Heat shock protein 70, Flt3L Fms-related tyrosine kinase 3 ligand, mAb monoclonal antibody.aActively followed in clinical trials only in combination with pNGVL4a vaccines. Table 1Therapeutic HPV vaccines actively followed in clinical trials for either precursor lesions or cancer, sorted by vaccine type and highest clinical phase reachedVaccine nameVaccine typeDeveloperVaccine compositionIndicationHighest clinical phaseHPV type and protein/peptide targetedDelivery system/adjuvanted byVGX-3100DNAInovio Pharmaceuticals / ApolloBioHPV16 E6/E7 & HPV18 E6/E7Precursor lesionsIIIINO-3112/MEDI0457DNAInovio PharmaceuticalsHPV16 E6/E7 & HPV18 E6/E7INO-9012 (DNA vector encoding IL-12)CancerIIpNGVL4a “family”DNAJohns Hopkins/PapivaxpNGVL4a-Sig/E7(detox)/HSP70 & pNGVL4a-CRT/E7(detox): HPV16 E7pNGVL4a-CRTE6E7L2 (PVX-4): HPV16 E6/E7/L2pBI-11 (PVX-8): HPV16 E6/E7 & HPV18 E6/E7 + Hsp70Hsp70 or calreticulinPrecursor lesions & cancerIIIIGX-188EDNAGenexineHPV16 E6/E7 & HPV18 E6/E7Flt3L + GX-I7(long-acting IL-7)CancerIIVB10.16DNANykodeHPV16 E6/E7CCL3L1CancerIINWRD08DNANewish TechnologyHPV16 E6/E7 & HPV18 E6/E7-Precursor lesionsIBNT113mRNABioNTechHPV16 E6/E7Lipoplex particlesCancerII/IIIRG002mRNARinuaGene BiotechHPV16/18 E2/E6/E7Lipid nanoparticlesPrecursor lesionsI/IICD40HVacProteinEnnoDCHPV16 E6/E7Anti-CD40 mAb, poly-ICLCCancerI/IITA-CINaProteinJohns Hopkins/PapivaxHPV16 E6/E7/L2-CancerIPDS0101Synthetic long peptidesPDS Biotech6 HPV16 E6/E7 synthetic long peptides (SLPs)Cationic lipid nanoparticlesCancerIIIISA101/101bSynthetic long peptidesISA Pharmaceuticals (currently ISAbella Pharma)13 (for ISA101) or 12 (for ISA101b) HPV16 E6/E7 overlapping SLPs: E61-32, E619-50, E641-65, E655-80, E671-95, E685-109, E691-122, E6109-140, E6127-158, E71-35, E722-56, E743-77 (only in ISA101), E764-98MontanideCancerIIPepCanSynthetic long peptidesUniv. of Arkansas4 HPV16 E6 SLPs: E61-45, E646-80, E681-115, E6116-158Candida albicans skin test reagentCancerI/IICUE-101Short peptideCue BiopharmaHPV16 E711-20, HLA-A2-restrictedFusion protein of HLA-A2, HPV16 E711-20, IL-2, and IgG1 Fc domainCancerIIPRGN-2009Viral vectorPrecigen35 non-HLA-restricted CTL epitopes of HPV16 E5/E6/E7 & HPV18 E6/E7GC46 gorilla adenovirusCancerIIVvax001Viral vectorViciniVaxHPV16 E6/E7Semliki Forest virus repliconPrecursor lesionsIITA-HPVaViral vectorJohns Hopkins/PapivaxHPV16 E6/E7 & HPV18 E6/E7Vaccinia virusPrecursor lesions & cancerIIITG4001Viral vectorTransgeneHPV16 E6/E7Modified Vaccinia Ankara virus (MVA); IL-2CancerI/IIIGMKK16E7Bacterial vectorNihon Univ., TokyoHPV16 E7Lactobacillus paracaseiPrecursor lesionsI/IIHsp70 Heat shock protein 70, Flt3L Fms-related tyrosine kinase 3 ligand, mAb monoclonal antibody.aActively followed in clinical trials only in combination with pNGVL4a vaccines. Therapeutic HPV vaccines actively followed in clinical trials for either precursor lesions or cancer, sorted by vaccine type and highest clinical phase reached pNGVL4a-Sig/E7(detox)/HSP70 & pNGVL4a-CRT/E7(detox): HPV16 E7 pNGVL4a-CRTE6E7L2 (PVX-4): HPV16 E6/E7/L2pBI-11 (PVX-8): HPV16 E6/E7 & HPV18 E6/E7 + Hsp70 II II Flt3L + GX-I7 (long-acting IL-7) I II Hsp70 Heat shock protein 70, Flt3L Fms-related tyrosine kinase 3 ligand, mAb monoclonal antibody. aActively followed in clinical trials only in combination with pNGVL4a vaccines. Vaccines against precursor lesions Several vaccines have been tested in HPV-mediated precursor lesions (Table 2). These include DNA vaccines (VGX-3100, pNGVL4a family vaccines, NWRD08), one viral vector-based vaccine (Vvax001) and one bacterial vector-based vaccine (IGMKK16E7). Vaccines that have been tested in precursor lesions, but are currently only pursued in cancer, are listed in the “Advanced Cancers” section.DNA vaccinesVGX-3100, targeting HPV16/18 E6/E7, has been tested in cervical, vulvar, anal, and peri-anal intraepithelial neoplasia grade 2/3 (CIN2/3, VIN2/3, AIN2/3, and PAIN2/3, respectively). In all trials, VGX-3100 was well tolerated, mainly leading to mild to moderate adverse events (AEs). Nevertheless, around 5–15% of patients across the different studies experienced grade ≥3 AEs, making VGX-3100 the least well tolerated HPV therapeutic vaccine. The vaccine, which was administered with electroporation, was first tested in a phase I trial on patients that had undergone surgery following CIN2/3 (NCT0068541239), where it was shown to be safe and gave indications of specific T cell induction. Several phase II trials were then completed, in which VGX-3100 showed promising results. In the HPV-003 trial (completed in 2014), 49.5% of vaccinated HPV16/18+ CIN2/3 patients experienced histopathological regression (versus 30.6% in the placebo group), and 40.2% reached HPV clearance (versus 14.3% in placebo group)40,41. Combination with local application of the TLR7 agonist imiquimod was shown to enhance the effect of the vaccine in the HPV-201 trial (completed in 2020)42, where HPV16/18+ VIN2/3 patients were treated with either the vaccine alone or the vaccine combined with imiquimod. At week 48, the combinatorial treatment led to absence of high-grade VIN and HPV16/18 clearance in 37.5% of patients, while this occurred in 15% of the patients that received the vaccine only. A phase II trial on AIN2/3 and PAIN2/3 (HPV-203) was completed in 2020 and showed a complete response of 9.1%43. VGX-3100 was also tested as monotherapy in two phase III studies as treatment for HPV16/18+ CIN2/3: the REVEAL1 (completed in 2020) and REVEAL2 trials (completed in 2022)44,45. In REVEAL1, 22.5% of the 138 vaccinated patients reached viral clearance and showed no evidence of CIN2/3 at week 36, against 11.1% of the 63 patients in the placebo group. At week 36 of REVEAL2, in the ITT (intention-to-treat) population, 27.6% of the treated patients exhibited no signs of CIN2/3 or HPV16/18 positivity anymore, vs. 8.7% in the placebo group. In a subgroup analysis of patients positive for an unspecified biomarker (n = 25), 28.6% of the treated patients exhibited no signs of CIN2/3 or HPV16/18 positivity, while this was not the case for any of the control patients. VGX-3100 is currently pursued by INOVIO’s Chinese partner, ApolloBio in another phase III trial.Vaccines from the pNGVL4a family include pNGVL4a-Sig/E7(detox)/HSP70, pNGVL4a-CRT/E7(detox) (both targeting HPV16 E7), PVX-4 (also called pNGVL4a-CRTE6E7L2, targeting HPVHPV16 E6/E7/L2) and PVX-8 (also called pBI-11, a construct targeting HPV16 E6/E7 and HPV18 E6/E7 and fused with Hsp70). They have been tested in low- and high-grade cervical precursor lesions, alone or in combination with imiquimod and other HPV vaccines such as vaccinia virus-based TA-HPV (targeting HPV16 E6/E7 and HPV18 E6/E7) and protein-based vaccine TA-CIN (targeting HPV16 L2/E6/E7), which had been proven to be safe on successfully treated HPV16+ cervical cancer patients (NCT0240522146). The combination with TA-CIN was named PVX-2 (pNGVL4a-Sig/E7(detox)/HSP70 + TA-CIN) or PVX-6 (PVX-4 + TA-CIN), while the combination of PVX-8 with TA-HPV is PVX-7. Phase I clinical trials demonstrated a good safety profile, no serious AEs being recorded in any of the trials. In a recent phase I trial (completed in 2023; NCT00788164) where the pNGVL4a-Sig/E7(detox)/HSP70 vaccine was tested in combination with the viral vector-based vaccine TA-HPV and topical imiquimod, 41.7% of HPV16+ CIN3 patients displayed complete histological regression (all dose groups combined)47. In the highest dose group, this was achieved in 50% of the patients. PVX-2, the combination of the same vaccine with the protein-based vaccine TA-CIN, was well tolerated in HPV16+ low-grade cervical lesions patients in a phase II trial (PVX2TACIN17368)48. However, the study was terminated due to lack of funding. The NCT00988559 trial (completed in 2016), conducted in 39 HPV16+ CIN2/3 patients, combined pNGVL4a-CRT/E7 (Detox) with resection of the lesion at week 15, as well as local imiquimod application in some of the treatment groups49. At week 15 before the resection procedure, 16.7% to 33% of patients displayed an absence of CIN2/3 lesions. Three further trials, assessing PVX-4, PVX-6 and PVX-8, are currently recruiting (NCT04131413, NCT03913117) or not yet recruiting (NCT06210854).NWRD08 targets HPV16/18 E6/E7 and is currently being tested on HPV16/18+ CIN2/3 in a non-randomized, open-label phase I trial (NCT06276101), for which no further information is available at the moment.mRNA vaccineRG002 is an mRNA-based vaccine targeting HPV16/18 E2, E6, and E7. This vaccine is currently entering a phase I/II clinical trial for the treatment of HPV16/18+ CIN2/3 patients (NCT06273553, not yet recruiting).Viral and bacterial vector vaccinesVvax001, based on Semliki Forest virus, targets HPV16 E6/E7. It was first tested in a phase I study on patients with a history of CIN2/3 or cervical cancer (Vvax001-UMCG-01), where the vaccine was well tolerated and resulted in E6/E7-specific responses in IFNγ ELISpots in 83.3% of patients50. Results for a phase II study testing the effect of Vvax001 on HPV16+ CIN3 patients (Vvax001-UMCG-02) were recently released51. 94% of patients experienced an overall reduction in lesion size, while 50% exhibited histopathological regression to CIN1 or less (with 3/18 patients achieving complete regression). Additionally, 63% of patients displayed HPV16 clearance.IGMKK16E7 vaccine contains L. paracasei bacteria harboring HPV16 E7 at the cell surface. The vaccine was tested at different doses in the phase I/II MILACLE study on HPV16+ CIN2/3 patients (completed in 2022)52. IGMKK16E7 was overall well tolerated (two grade 3 AEs were reported in the low dose group). At week 24, a dose-dependent proportion of the patients displayed complete regression to normal histology (30.2% in the highest dose group vs 12.5% of placebo-treated patients).Table 2Therapeutic HPV vaccines actively followed in clinical trials for treatment of precursor lesionsVaccineTrial phaseIndicationCombination treatmentTrial typeTrial statusAcronym/IdentifierOutcome/ EfficacyRef.VGX-3100ICIN2/3 post surgery-Non-randomized, open-label,no control groupCompleted in 2011HPV001(NCT00685412)18 patients (6 patients per dose group).No patients with grade ≥3 AEs.IFNγ ELISpot response rate (week 16): 78%.ELISA response rate (week 16): 67% (HPV16 E6), 94% (HPV16 E7), 39% (HPV18 E6), 100% (HPV18 E7).39IIHPV16/18+ CIN2/3-Randomized, double-blind, placebo controlCompleted in 2014HPV-003(NCT01304524)107 treated patients vs 36 placebo.4.8% of patients with grade ≥3 AEs (vaccine) vs 2.4% of patients with grade ≥3 AEs (placebo).Histopathological regression (week 36): 49.5% (vaccine) vs 30.6% (placebo).Complete response (week 36): 40.2% (vaccine) vs 16.7% (placebo).40,41IIIHPV16/18+ CIN2/3-Randomized, quadruple-blind, placebo controlCompleted in 2020HPV-301 / REVEAL 1(NCT03185013)138 treated patients vs 63 placebo.9.6% of patients with grade ≥3 AEs (vaccine) vs 9.7% of patients with grade ≥3 AEs (placebo).Complete response (week 36):22.5% (vaccine) vs 11.1% (placebo).44IIHPV16/18+ VIN2/3ImiquimodRandomized, open-label,active controlCompleted in 2020HPV-201(NCT03180684)20 patients (vaccine) vs 8 patients (vaccine + imiquimod).a12% of patients with grade ≥3 AEs (vaccine) vs no patients with grade ≥3 AEs (placebo).Complete response (week 48):15% (vaccine) vs 37.5% (vaccine + imiquimod).42IIHPV16/18+ AIN2/3 or PAIN2/3-Open-label,no control groupCompleted in 2020HPV-203(NCT03499795)22 patients.4.4% of patients with grade ≥3 AEs.Complete response (week 36): 9.1%.43IIHIV+ HPV16/18+ AIN2/3 or PAIN2/3-Open-label,no control groupCompletedin 2024HPV-202(NCT03603808)N/A-IIIHPV16/18+ CIN2/3-Randomized, quadruple-blind, placebo controlCompleted in 2022HPV-303 / REVEAL 2(NCT03721978)21 treated patients vs 4 placebo.a14.3% of patients with grade ≥3 AEs (vaccine) vs no patients with grade ≥3 AEs (placebo).Complete response (week 36):28.6% (vaccine) vs 0% (placebo).45pNGVL4a-Sig/E7 (detox)/ HSP70I/IIHPV16+ CIN2/3-Non-randomized,open-label,no control groupCompleted in 2010JHOC-J0323(NCT00121173)15 patients (3–9 patients per dose group).No patients with grade ≥2 AEs.Complete response (week 15):33% in the highest dose cohort.147pNGVL4a-Sig/E7 (detox)/ HSP70IHPV16+ CIN3TA-HPV( + Imiquimod)Non-randomized,open-label,active controlCompleted in 2023J0656(NCT00788164)12 patientsa (3–6 patients per dose group).No patients with grade ≥2 AEs.Complete response (week 15): 41.7%b (33–50%c).47pNGVL4a-CRT/E7 (detox)IHPV16+ CIN2/3Resection( + Imiquimod)Non-randomized,open-label,no control groupCompleted in 2016J0866(NCT00988559)39 patientsa (6–9 patients per treatment group).No patients with grade ≥3 AEs.Complete response (week 15): 27.3%b (16.7%-33%c).49pNGVL4a Sig/E7 (detox)/ HSP70IIHPV16+ ASC-US, ASC-H or CIN1TA-CIN (combination treatment “PVX-2”)Open-label,no control groupTerminated (due to slow accrual/funding)PVX2TACIN17368(NCT03911076)11 patients.No patients with grade ≥2 AEs.48pNGVL4a-CRTE6E7L2(PVX-4)IHPV16+ CIN2/3-Non-randomized,open-label,no control groupRecruitingJ1955(NCT04131413)N/A-pNGVL4a-CRTE6E7L2(PVX-4)IHPV16+ ASC-US or CIN1(TA-CIN (combination treatment “PVX-6”))Non-randomized,open-label,no control groupRecruitingBB IND 18340(NCT03913117)N/A-pBI-11(PVX-8)IIHPV16/18+ ASC-US or CIN1-Randomized, triple-blind, placebo controlNot yet recruitingCRMS-83553(NCT06210854)N/A-NWRD08N/AHPV16/18+ CIN1-3-Non-randomized,open-label,no control groupUnknownNEWISH-HPV-001(NCT05905354)N/A-IHPV16/18+ CIN2/3-Open-label,no control groupRecruitingNEWISH-HPV-101(NCT06276101)N/A-RG002I/IIHPV16/18+ CIN2/3-Open-label,no control groupNot yet recruitingNCT06273553N/A-Vvax001IHistory of CIN2/3 or cervical cancer-Non-randomized,Open-label,no control groupCompleted in 2017Vvax001-UMCG-01(NCT03141463)12 patients (3 patients per dose group).No patients with grade ≥3 AEs.IFNγ ELISpot HPV16 E6/E7-specific response (week 7): 83.3%50IIHPV16+ CIN3-Open-label,no control groupUnknownVvax001-UMCG-02(NCT06015854)18 patients.No patients with grade ≥3 AEs.Histopathological regression (week 25): 50%.Complete response (week 25): 16.7%b.51IGMKK16E7I/IIHPV16+ CIN2/3-Randomized, double-blind, placebo controlCompleted in 2022MILACLE/jRTC20311900124 treated patients (39-43 patients per dose group) vs 40 placebo.1.6%b of patients with grade ≥3 AEs (vaccine) vs no patients with grade ≥3 AEs (placebo).Complete response (week 24): 12.2% (low vaccine dose) vs 15.0% (intermediate vaccine dose) vs 30.2% (high vaccine dose) vs 12.5% (placebo).52aNumber of patients refers to the number of patients analyzed regarding vaccine efficacy in the study.bValue was calculated by the authors using the available data.cDepending on the dose group. DNA vaccinesVGX-3100, targeting HPV16/18 E6/E7, has been tested in cervical, vulvar, anal, and peri-anal intraepithelial neoplasia grade 2/3 (CIN2/3, VIN2/3, AIN2/3, and PAIN2/3, respectively). In all trials, VGX-3100 was well tolerated, mainly leading to mild to moderate adverse events (AEs). Nevertheless, around 5–15% of patients across the different studies experienced grade ≥3 AEs, making VGX-3100 the least well tolerated HPV therapeutic vaccine. The vaccine, which was administered with electroporation, was first tested in a phase I trial on patients that had undergone surgery following CIN2/3 (NCT0068541239), where it was shown to be safe and gave indications of specific T cell induction. Several phase II trials were then completed, in which VGX-3100 showed promising results. In the HPV-003 trial (completed in 2014), 49.5% of vaccinated HPV16/18+ CIN2/3 patients experienced histopathological regression (versus 30.6% in the placebo group), and 40.2% reached HPV clearance (versus 14.3% in placebo group)40,41. Combination with local application of the TLR7 agonist imiquimod was shown to enhance the effect of the vaccine in the HPV-201 trial (completed in 2020)42, where HPV16/18+ VIN2/3 patients were treated with either the vaccine alone or the vaccine combined with imiquimod. At week 48, the combinatorial treatment led to absence of high-grade VIN and HPV16/18 clearance in 37.5% of patients, while this occurred in 15% of the patients that received the vaccine only. A phase II trial on AIN2/3 and PAIN2/3 (HPV-203) was completed in 2020 and showed a complete response of 9.1%43. VGX-3100 was also tested as monotherapy in two phase III studies as treatment for HPV16/18+ CIN2/3: the REVEAL1 (completed in 2020) and REVEAL2 trials (completed in 2022)44,45. In REVEAL1, 22.5% of the 138 vaccinated patients reached viral clearance and showed no evidence of CIN2/3 at week 36, against 11.1% of the 63 patients in the placebo group. At week 36 of REVEAL2, in the ITT (intention-to-treat) population, 27.6% of the treated patients exhibited no signs of CIN2/3 or HPV16/18 positivity anymore, vs. 8.7% in the placebo group. In a subgroup analysis of patients positive for an unspecified biomarker (n = 25), 28.6% of the treated patients exhibited no signs of CIN2/3 or HPV16/18 positivity, while this was not the case for any of the control patients. VGX-3100 is currently pursued by INOVIO’s Chinese partner, ApolloBio in another phase III trial.Vaccines from the pNGVL4a family include pNGVL4a-Sig/E7(detox)/HSP70, pNGVL4a-CRT/E7(detox) (both targeting HPV16 E7), PVX-4 (also called pNGVL4a-CRTE6E7L2, targeting HPVHPV16 E6/E7/L2) and PVX-8 (also called pBI-11, a construct targeting HPV16 E6/E7 and HPV18 E6/E7 and fused with Hsp70). They have been tested in low- and high-grade cervical precursor lesions, alone or in combination with imiquimod and other HPV vaccines such as vaccinia virus-based TA-HPV (targeting HPV16 E6/E7 and HPV18 E6/E7) and protein-based vaccine TA-CIN (targeting HPV16 L2/E6/E7), which had been proven to be safe on successfully treated HPV16+ cervical cancer patients (NCT0240522146). The combination with TA-CIN was named PVX-2 (pNGVL4a-Sig/E7(detox)/HSP70 + TA-CIN) or PVX-6 (PVX-4 + TA-CIN), while the combination of PVX-8 with TA-HPV is PVX-7. Phase I clinical trials demonstrated a good safety profile, no serious AEs being recorded in any of the trials. In a recent phase I trial (completed in 2023; NCT00788164) where the pNGVL4a-Sig/E7(detox)/HSP70 vaccine was tested in combination with the viral vector-based vaccine TA-HPV and topical imiquimod, 41.7% of HPV16+ CIN3 patients displayed complete histological regression (all dose groups combined)47. In the highest dose group, this was achieved in 50% of the patients. PVX-2, the combination of the same vaccine with the protein-based vaccine TA-CIN, was well tolerated in HPV16+ low-grade cervical lesions patients in a phase II trial (PVX2TACIN17368)48. However, the study was terminated due to lack of funding. The NCT00988559 trial (completed in 2016), conducted in 39 HPV16+ CIN2/3 patients, combined pNGVL4a-CRT/E7 (Detox) with resection of the lesion at week 15, as well as local imiquimod application in some of the treatment groups49. At week 15 before the resection procedure, 16.7% to 33% of patients displayed an absence of CIN2/3 lesions. Three further trials, assessing PVX-4, PVX-6 and PVX-8, are currently recruiting (NCT04131413, NCT03913117) or not yet recruiting (NCT06210854).NWRD08 targets HPV16/18 E6/E7 and is currently being tested on HPV16/18+ CIN2/3 in a non-randomized, open-label phase I trial (NCT06276101), for which no further information is available at the moment. DNA vaccines VGX-3100, targeting HPV16/18 E6/E7, has been tested in cervical, vulvar, anal, and peri-anal intraepithelial neoplasia grade 2/3 (CIN2/3, VIN2/3, AIN2/3, and PAIN2/3, respectively). In all trials, VGX-3100 was well tolerated, mainly leading to mild to moderate adverse events (AEs). Nevertheless, around 5–15% of patients across the different studies experienced grade ≥3 AEs, making VGX-3100 the least well tolerated HPV therapeutic vaccine. The vaccine, which was administered with electroporation, was first tested in a phase I trial on patients that had undergone surgery following CIN2/3 (NCT0068541239), where it was shown to be safe and gave indications of specific T cell induction. Several phase II trials were then completed, in which VGX-3100 showed promising results. In the HPV-003 trial (completed in 2014), 49.5% of vaccinated HPV16/18+ CIN2/3 patients experienced histopathological regression (versus 30.6% in the placebo group), and 40.2% reached HPV clearance (versus 14.3% in placebo group)40,41. Combination with local application of the TLR7 agonist imiquimod was shown to enhance the effect of the vaccine in the HPV-201 trial (completed in 2020)42, where HPV16/18+ VIN2/3 patients were treated with either the vaccine alone or the vaccine combined with imiquimod. At week 48, the combinatorial treatment led to absence of high-grade VIN and HPV16/18 clearance in 37.5% of patients, while this occurred in 15% of the patients that received the vaccine only. A phase II trial on AIN2/3 and PAIN2/3 (HPV-203) was completed in 2020 and showed a complete response of 9.1%43. VGX-3100 was also tested as monotherapy in two phase III studies as treatment for HPV16/18+ CIN2/3: the REVEAL1 (completed in 2020) and REVEAL2 trials (completed in 2022)44,45. In REVEAL1, 22.5% of the 138 vaccinated patients reached viral clearance and showed no evidence of CIN2/3 at week 36, against 11.1% of the 63 patients in the placebo group. At week 36 of REVEAL2, in the ITT (intention-to-treat) population, 27.6% of the treated patients exhibited no signs of CIN2/3 or HPV16/18 positivity anymore, vs. 8.7% in the placebo group. In a subgroup analysis of patients positive for an unspecified biomarker (n = 25), 28.6% of the treated patients exhibited no signs of CIN2/3 or HPV16/18 positivity, while this was not the case for any of the control patients. VGX-3100 is currently pursued by INOVIO’s Chinese partner, ApolloBio in another phase III trial. Vaccines from the pNGVL4a family include pNGVL4a-Sig/E7(detox)/HSP70, pNGVL4a-CRT/E7(detox) (both targeting HPV16 E7), PVX-4 (also called pNGVL4a-CRTE6E7L2, targeting HPVHPV16 E6/E7/L2) and PVX-8 (also called pBI-11, a construct targeting HPV16 E6/E7 and HPV18 E6/E7 and fused with Hsp70). They have been tested in low- and high-grade cervical precursor lesions, alone or in combination with imiquimod and other HPV vaccines such as vaccinia virus-based TA-HPV (targeting HPV16 E6/E7 and HPV18 E6/E7) and protein-based vaccine TA-CIN (targeting HPV16 L2/E6/E7), which had been proven to be safe on successfully treated HPV16+ cervical cancer patients (NCT0240522146). The combination with TA-CIN was named PVX-2 (pNGVL4a-Sig/E7(detox)/HSP70 + TA-CIN) or PVX-6 (PVX-4 + TA-CIN), while the combination of PVX-8 with TA-HPV is PVX-7. Phase I clinical trials demonstrated a good safety profile, no serious AEs being recorded in any of the trials. In a recent phase I trial (completed in 2023; NCT00788164) where the pNGVL4a-Sig/E7(detox)/HSP70 vaccine was tested in combination with the viral vector-based vaccine TA-HPV and topical imiquimod, 41.7% of HPV16+ CIN3 patients displayed complete histological regression (all dose groups combined)47. In the highest dose group, this was achieved in 50% of the patients. PVX-2, the combination of the same vaccine with the protein-based vaccine TA-CIN, was well tolerated in HPV16+ low-grade cervical lesions patients in a phase II trial (PVX2TACIN17368)48. However, the study was terminated due to lack of funding. The NCT00988559 trial (completed in 2016), conducted in 39 HPV16+ CIN2/3 patients, combined pNGVL4a-CRT/E7 (Detox) with resection of the lesion at week 15, as well as local imiquimod application in some of the treatment groups49. At week 15 before the resection procedure, 16.7% to 33% of patients displayed an absence of CIN2/3 lesions. Three further trials, assessing PVX-4, PVX-6 and PVX-8, are currently recruiting (NCT04131413, NCT03913117) or not yet recruiting (NCT06210854). NWRD08 targets HPV16/18 E6/E7 and is currently being tested on HPV16/18+ CIN2/3 in a non-randomized, open-label phase I trial (NCT06276101), for which no further information is available at the moment. mRNA vaccineRG002 is an mRNA-based vaccine targeting HPV16/18 E2, E6, and E7. This vaccine is currently entering a phase I/II clinical trial for the treatment of HPV16/18+ CIN2/3 patients (NCT06273553, not yet recruiting). mRNA vaccine RG002 is an mRNA-based vaccine targeting HPV16/18 E2, E6, and E7. This vaccine is currently entering a phase I/II clinical trial for the treatment of HPV16/18+ CIN2/3 patients (NCT06273553, not yet recruiting). Viral and bacterial vector vaccinesVvax001, based on Semliki Forest virus, targets HPV16 E6/E7. It was first tested in a phase I study on patients with a history of CIN2/3 or cervical cancer (Vvax001-UMCG-01), where the vaccine was well tolerated and resulted in E6/E7-specific responses in IFNγ ELISpots in 83.3% of patients50. Results for a phase II study testing the effect of Vvax001 on HPV16+ CIN3 patients (Vvax001-UMCG-02) were recently released51. 94% of patients experienced an overall reduction in lesion size, while 50% exhibited histopathological regression to CIN1 or less (with 3/18 patients achieving complete regression). Additionally, 63% of patients displayed HPV16 clearance.IGMKK16E7 vaccine contains L. paracasei bacteria harboring HPV16 E7 at the cell surface. The vaccine was tested at different doses in the phase I/II MILACLE study on HPV16+ CIN2/3 patients (completed in 2022)52. IGMKK16E7 was overall well tolerated (two grade 3 AEs were reported in the low dose group). At week 24, a dose-dependent proportion of the patients displayed complete regression to normal histology (30.2% in the highest dose group vs 12.5% of placebo-treated patients). Viral and bacterial vector vaccines Vvax001, based on Semliki Forest virus, targets HPV16 E6/E7. It was first tested in a phase I study on patients with a history of CIN2/3 or cervical cancer (Vvax001-UMCG-01), where the vaccine was well tolerated and resulted in E6/E7-specific responses in IFNγ ELISpots in 83.3% of patients50. Results for a phase II study testing the effect of Vvax001 on HPV16+ CIN3 patients (Vvax001-UMCG-02) were recently released51. 94% of patients experienced an overall reduction in lesion size, while 50% exhibited histopathological regression to CIN1 or less (with 3/18 patients achieving complete regression). Additionally, 63% of patients displayed HPV16 clearance. IGMKK16E7 vaccine contains L. paracasei bacteria harboring HPV16 E7 at the cell surface. The vaccine was tested at different doses in the phase I/II MILACLE study on HPV16+ CIN2/3 patients (completed in 2022)52. IGMKK16E7 was overall well tolerated (two grade 3 AEs were reported in the low dose group). At week 24, a dose-dependent proportion of the patients displayed complete regression to normal histology (30.2% in the highest dose group vs 12.5% of placebo-treated patients). Table 2Therapeutic HPV vaccines actively followed in clinical trials for treatment of precursor lesionsVaccineTrial phaseIndicationCombination treatmentTrial typeTrial statusAcronym/IdentifierOutcome/ EfficacyRef.VGX-3100ICIN2/3 post surgery-Non-randomized, open-label,no control groupCompleted in 2011HPV001(NCT00685412)18 patients (6 patients per dose group).No patients with grade ≥3 AEs.IFNγ ELISpot response rate (week 16): 78%.ELISA response rate (week 16): 67% (HPV16 E6), 94% (HPV16 E7), 39% (HPV18 E6), 100% (HPV18 E7).39IIHPV16/18+ CIN2/3-Randomized, double-blind, placebo controlCompleted in 2014HPV-003(NCT01304524)107 treated patients vs 36 placebo.4.8% of patients with grade ≥3 AEs (vaccine) vs 2.4% of patients with grade ≥3 AEs (placebo).Histopathological regression (week 36): 49.5% (vaccine) vs 30.6% (placebo).Complete response (week 36): 40.2% (vaccine) vs 16.7% (placebo).40,41IIIHPV16/18+ CIN2/3-Randomized, quadruple-blind, placebo controlCompleted in 2020HPV-301 / REVEAL 1(NCT03185013)138 treated patients vs 63 placebo.9.6% of patients with grade ≥3 AEs (vaccine) vs 9.7% of patients with grade ≥3 AEs (placebo).Complete response (week 36):22.5% (vaccine) vs 11.1% (placebo).44IIHPV16/18+ VIN2/3ImiquimodRandomized, open-label,active controlCompleted in 2020HPV-201(NCT03180684)20 patients (vaccine) vs 8 patients (vaccine + imiquimod).a12% of patients with grade ≥3 AEs (vaccine) vs no patients with grade ≥3 AEs (placebo).Complete response (week 48):15% (vaccine) vs 37.5% (vaccine + imiquimod).42IIHPV16/18+ AIN2/3 or PAIN2/3-Open-label,no control groupCompleted in 2020HPV-203(NCT03499795)22 patients.4.4% of patients with grade ≥3 AEs.Complete response (week 36): 9.1%.43IIHIV+ HPV16/18+ AIN2/3 or PAIN2/3-Open-label,no control groupCompletedin 2024HPV-202(NCT03603808)N/A-IIIHPV16/18+ CIN2/3-Randomized, quadruple-blind, placebo controlCompleted in 2022HPV-303 / REVEAL 2(NCT03721978)21 treated patients vs 4 placebo.a14.3% of patients with grade ≥3 AEs (vaccine) vs no patients with grade ≥3 AEs (placebo).Complete response (week 36):28.6% (vaccine) vs 0% (placebo).45pNGVL4a-Sig/E7 (detox)/ HSP70I/IIHPV16+ CIN2/3-Non-randomized,open-label,no control groupCompleted in 2010JHOC-J0323(NCT00121173)15 patients (3–9 patients per dose group).No patients with grade ≥2 AEs.Complete response (week 15):33% in the highest dose cohort.147pNGVL4a-Sig/E7 (detox)/ HSP70IHPV16+ CIN3TA-HPV( + Imiquimod)Non-randomized,open-label,active controlCompleted in 2023J0656(NCT00788164)12 patientsa (3–6 patients per dose group).No patients with grade ≥2 AEs.Complete response (week 15): 41.7%b (33–50%c).47pNGVL4a-CRT/E7 (detox)IHPV16+ CIN2/3Resection( + Imiquimod)Non-randomized,open-label,no control groupCompleted in 2016J0866(NCT00988559)39 patientsa (6–9 patients per treatment group).No patients with grade ≥3 AEs.Complete response (week 15): 27.3%b (16.7%-33%c).49pNGVL4a Sig/E7 (detox)/ HSP70IIHPV16+ ASC-US, ASC-H or CIN1TA-CIN (combination treatment “PVX-2”)Open-label,no control groupTerminated (due to slow accrual/funding)PVX2TACIN17368(NCT03911076)11 patients.No patients with grade ≥2 AEs.48pNGVL4a-CRTE6E7L2(PVX-4)IHPV16+ CIN2/3-Non-randomized,open-label,no control groupRecruitingJ1955(NCT04131413)N/A-pNGVL4a-CRTE6E7L2(PVX-4)IHPV16+ ASC-US or CIN1(TA-CIN (combination treatment “PVX-6”))Non-randomized,open-label,no control groupRecruitingBB IND 18340(NCT03913117)N/A-pBI-11(PVX-8)IIHPV16/18+ ASC-US or CIN1-Randomized, triple-blind, placebo controlNot yet recruitingCRMS-83553(NCT06210854)N/A-NWRD08N/AHPV16/18+ CIN1-3-Non-randomized,open-label,no control groupUnknownNEWISH-HPV-001(NCT05905354)N/A-IHPV16/18+ CIN2/3-Open-label,no control groupRecruitingNEWISH-HPV-101(NCT06276101)N/A-RG002I/IIHPV16/18+ CIN2/3-Open-label,no control groupNot yet recruitingNCT06273553N/A-Vvax001IHistory of CIN2/3 or cervical cancer-Non-randomized,Open-label,no control groupCompleted in 2017Vvax001-UMCG-01(NCT03141463)12 patients (3 patients per dose group).No patients with grade ≥3 AEs.IFNγ ELISpot HPV16 E6/E7-specific response (week 7): 83.3%50IIHPV16+ CIN3-Open-label,no control groupUnknownVvax001-UMCG-02(NCT06015854)18 patients.No patients with grade ≥3 AEs.Histopathological regression (week 25): 50%.Complete response (week 25): 16.7%b.51IGMKK16E7I/IIHPV16+ CIN2/3-Randomized, double-blind, placebo controlCompleted in 2022MILACLE/jRTC20311900124 treated patients (39-43 patients per dose group) vs 40 placebo.1.6%b of patients with grade ≥3 AEs (vaccine) vs no patients with grade ≥3 AEs (placebo).Complete response (week 24): 12.2% (low vaccine dose) vs 15.0% (intermediate vaccine dose) vs 30.2% (high vaccine dose) vs 12.5% (placebo).52aNumber of patients refers to the number of patients analyzed regarding vaccine efficacy in the study.bValue was calculated by the authors using the available data.cDepending on the dose group. Therapeutic HPV vaccines actively followed in clinical trials for treatment of precursor lesions Non-randomized, open-label, no control group HPV001 (NCT00685412) 18 patients (6 patients per dose group). No patients with grade ≥3 AEs. IFNγ ELISpot response rate (week 16): 78%. ELISA response rate (week 16): 67% (HPV16 E6), 94% (HPV16 E7), 39% (HPV18 E6), 100% (HPV18 E7). HPV-003 (NCT01304524) 107 treated patients vs 36 placebo. 4.8% of patients with grade ≥3 AEs (vaccine) vs 2.4% of patients with grade ≥3 AEs (placebo). Histopathological regression (week 36): 49.5% (vaccine) vs 30.6% (placebo). Complete response (week 36): 40.2% (vaccine) vs 16.7% (placebo). HPV-301 / REVEAL 1 (NCT03185013) 138 treated patients vs 63 placebo. 9.6% of patients with grade ≥3 AEs (vaccine) vs 9.7% of patients with grade ≥3 AEs (placebo). Complete response (week 36): 22.5% (vaccine) vs 11.1% (placebo). Randomized, open-label, active control HPV-201 (NCT03180684) 20 patients (vaccine) vs 8 patients (vaccine + imiquimod).a 12% of patients with grade ≥3 AEs (vaccine) vs no patients with grade ≥3 AEs (placebo). Complete response (week 48): 15% (vaccine) vs 37.5% (vaccine + imiquimod). Open-label, no control group HPV-203 (NCT03499795) 22 patients. 4.4% of patients with grade ≥3 AEs. Complete response (week 36): 9.1%. Open-label, no control group Completed in 2024 HPV-202 (NCT03603808) HPV-303 / REVEAL 2 (NCT03721978) 21 treated patients vs 4 placebo.a 14.3% of patients with grade ≥3 AEs (vaccine) vs no patients with grade ≥3 AEs (placebo). Complete response (week 36): 28.6% (vaccine) vs 0% (placebo). Non-randomized, open-label, no control group JHOC-J0323 (NCT00121173) 15 patients (3–9 patients per dose group). No patients with grade ≥2 AEs. Complete response (week 15): 33% in the highest dose cohort. TA-HPV ( + Imiquimod) Non-randomized, open-label, active control J0656 (NCT00788164) 12 patientsa (3–6 patients per dose group). No patients with grade ≥2 AEs. Complete response (week 15): 41.7%b (33–50%c). Resection ( + Imiquimod) Non-randomized, open-label, no control group J0866 (NCT00988559) 39 patientsa (6–9 patients per treatment group). No patients with grade ≥3 AEs. Complete response (week 15): 27.3%b (16.7%-33%c). Open-label, no control group PVX2TACIN17368 (NCT03911076) 11 patients. No patients with grade ≥2 AEs. pNGVL4a-CRTE6E7L2 (PVX-4) Non-randomized, open-label, no control group J1955 (NCT04131413) pNGVL4a-CRTE6E7L2 (PVX-4) Non-randomized, open-label, no control group BB IND 18340 (NCT03913117) pBI-11 (PVX-8) CRMS-83553 (NCT06210854) Non-randomized, open-label, no control group NEWISH-HPV-001 (NCT05905354) Open-label, no control group NEWISH-HPV-101 (NCT06276101) Open-label, no control group Non-randomized, Open-label, no control group Vvax001-UMCG-01 (NCT03141463) 12 patients (3 patients per dose group). No patients with grade ≥3 AEs. IFNγ ELISpot HPV16 E6/E7-specific response (week 7): 83.3% Open-label, no control group Vvax001-UMCG-02 (NCT06015854) 18 patients. No patients with grade ≥3 AEs. Histopathological regression (week 25): 50%. Complete response (week 25): 16.7%b. MILACLE/ jRTC20311900 124 treated patients (39-43 patients per dose group) vs 40 placebo. 1.6%b of patients with grade ≥3 AEs (vaccine) vs no patients with grade ≥3 AEs (placebo). Complete response (week 24): 12.2% (low vaccine dose) vs 15.0% (intermediate vaccine dose) vs 30.2% (high vaccine dose) vs 12.5% (placebo). aNumber of patients refers to the number of patients analyzed regarding vaccine efficacy in the study. bValue was calculated by the authors using the available data. cDepending on the dose group. Vaccines against advanced cancers Therapeutic vaccines were also tested in advanced cancer settings, albeit almost exclusively in combination with immune checkpoint blockade (ICB) or standard of care chemo- or radiotherapy (Table 3). Vaccines derived from the pNGVL4a construct and VGX-3100 (as INO-3112 contains VGX-3100) are the only ones currently still being tested for both precursor lesions and advanced cancers. Some vaccines were tested for precursor lesions, but were abandoned for this indication. These include GX-188E (NCT02139267), ISA101(b) (NL14015.000.06), VB10.16 (NCT02529930), TG4001 (NCT01022346) and PepCan (NCT02481414). However, they are still actively pursued in combination with other therapies in advanced cancer treatment (respective studies discussed below). Others, such as CD40HVac or BNT-113, have exclusively been tested in the cancer setting.DNA vaccinesTwo trials are currently ongoing with the pNGVL4a-Hsp70 construct pBI-11 (PVX-8, targeting HVP16/18 E6/E7), combining it with the viral vector-based HPV16/18 E6/E7 vaccine TA-HPV (combination treatment PVX-7) in the context of hrHPV+ PD-L1+ recurrent/metastatic oropharyngeal squamous cell carcinoma (NCT05799144, phase II, recruiting53) and advanced cervical cancer (NCT06315257, phase I, recruiting).GX-188E is a DNA vaccine targeting HPV16 E6/E7 and HPV18 E6/E7, which was recently tested in a phase I/II trial in combination with pembrolizumab (anti-PD1) in HPV16/18+ recurrent/metastatic cervical cancer (GX-188E-00554). At week 24, 35% of the 60 patients showcased an overall response, including 8.3% complete responses. The combination treatment was more successful in PD-L1+ than PD-L1− patients (38.9% vs 29.2% overall response rate). Two phase II trials are currently testing the combination of GX-188E with GX-I7 (a long-acting IL-7) and the anti-PD1 agents pembrolizumab (GENUINE55), or nivolumab (TRINITY), respectively. The GENUINE trial preliminary results showed major pathologic response in 63.6% of HPV16/18+ advanced, resectable head and neck squamous cell carcinoma and a complete response in 36.3% of patients.The DNA vaccine VB10.16 targets HPV16 E6/E7, and its efficacy was assessed in a phase II trial in combination with atezolizumab (anti-PD-L1) in HPV16+ recurrent/metastatic cervical cancer patients (VB-C-02). An overall response rate of 19.1% was achieved after 1 year, including 6.4% complete responses56. Another phase I/II trial (VB-C-03) is currently recruiting to test VB10.16 in HPV16+ PD-L1+ recurrent/metastatic oropharyngeal cancer patients, in combination with pembrolizumab57, while a phase II trial (VB-C-04) in HPV16+ PD-L1+ recurrent/metastatic cervical cancer was withdrawn due to strategic reasons, as announced in a press release in August 2024 (https://nykode.com/wp-content/uploads/2024/08/240821_VB1016-strategic-repositioning-PR-FINAL.pdf).INO-3112, also called MEDI0457, another DNA vaccine, associates VGX-3100 (encoding HPV16/18 E6/E7, cf. precursor lesions) with another DNA vector (INO-9012) encoding for IL-12. It entered three clinical trials for HPV-driven head and neck cancers (NCT04001413, NCT0316224, NCT03439085), all combining the vaccine with the PD-L1 inhibitor durvalumab. NCT04001413 was withdrawn due to funding reasons. In the phase Ib/IIa trial (NCT03162224), completed in 2021, a disease control rate of 44.8% and an overall response rate of 27.6% was observed58. In another phase II trial (NCT03439085)59, similar results were achieved, with a disease control rate of 37% and an overall response rate of 21%. The company announced its intention to soon launch a phase III trial where INO-3112 will be combined with an anti-PD1 agent (toripalimab-tpzi) in HPV16/18+ patients with locally advanced OPSCC (https://ir.inovio.com/news-releases/news-releases-details/2025/INOVIO-Highlights-Anticipated-2025-Milestones-and-2024-Key-Accomplishments/default.aspx).mRNA vaccineBNT113 is an mRNA vaccine specific for HPV16 E6/E7. In the phase I/II HARE-40 trial, completed in 2024, BNT113 was tested in 17 HPV16+ disease-free HNSCC patients (Arm 1A) and in 13 HPV16+ cancer patients (Arm 1B)60. Grade ≥3 adverse drug reactions were observed in 24% of patients, and specific immune responses were detected in both study arms. 71% of 7 patients in Arm 1B, that were evaluated with post-treatment tumor scans, achieved disease control. BNT113 is currently being further explored in combination with pembrolizumab in a phase II/III study on HPV16+ PD-L1+ recurrent/metastatic HNSCC (AHEAD-MERIT61). So far, 26.7% of patients experienced grade ≥3 AEs. The overall response rate was 40% (up to 48 months), and 4 out of 15 patients achieved complete response.Protein- and peptide-based vaccinesCD40HVac is a protein-based vaccine, while PDS0101, ISA101(b), CUE-101, and PepCan are all peptide-based vaccines.CD40HVac contains a fusion of HPV16 E6/E7 proteins and an anti-CD40 monoclonal antibody. The HPVDCVax phase I/II study is currently recruiting HPV16+ OPSCC patients to test the vaccine, adjuvanted by poly-ICLC. So far, 12 patients have been recruited for the lowest dose cohort (HPVDCVax), and preliminary results of this cohort indicate a good safety profile of the vaccine62. A phase IIb trial for HPV16+ OPSCC patients is already planned (https://www.biospace.com/press-releases/ennodc-unveils-the-next-generation-of-dendritic-cell-targeting-immunotherapies-supported-by-new-leadership-and-an-evolved-strategy).PDS0101, a vaccine consisting of six HPV16 E6/E7 synthetic long peptides, encapsulated in cationic lipid nanoparticles, has been and is currently being tested in multiple phase I/II and phase II trials (20-C-0045, IMMUNOCERV, VERSATILE-002, MC200710). A first phase III trial (VERSATILE-003) is currently ongoing. In the VERSATILE-002 phase II study (completed in 2025), PDS0101 was administered to HPV16+ PD-L1+ recurrent/metastatic HNSCC patients in combination with pembrolizumab63. The vaccine was well tolerated, with 13% of patients experiencing grade ≥3 AEs. 34% of patients displayed an overall response, including 7.5% exhibiting a complete response, with a median overall survival of 30 months. A recent press release underlined encouraging results for the low PD-L1-expressing population (https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/132-2025-news/1018-pds-biotech-sets-significant-benchmark-in-head-and-neck-canc2025-09-18-055003), which is especially hard to treat with conventional therapy. In the MC200710 phase I/II study, PDS0101 was also tested alone or in combination with pembrolizumab in patients with hrHPV+ advanced OPSCC64. While the overall response rate was 20% in the combination treatment group and 0% in the monotherapy group, high disease control rates of 70% and 100%, respectively, were observed. In the IMMUNOCERV study testing PDS0101 in combination with radiotherapy and cisplatin in advanced cervical cancer patients, 47% of patients experienced grade ≥3 AEs, 29% displayed over 90% gross tumor volume reduction at day 35 and 59% reached complete metabolic response by positron emission tomography computed tomography (PET CT)65.ISA101 and ISA101b, vaccines consisting of HPV16 E6/E7 synthetic long peptides, completed several phase I/II and phase II trials. While the E6 SLPs contained in ISA101 and ISA101b are identical, ISA101b contains three E7 SLPs, while ISA101 contains four, in this way covering seven more amino acids (c.f. Table 1). In the ISA-HPV-01-12 phase I/II trial (completed in 2018), the response to ISA101b compared to ISA101 was assessed with different doses alone or in combination with chemotherapy and IFNα in a total of 72 HPV16+ recurrent/metastatic cervical cancer patients66. Overall, 27.8% of patients experienced grade ≥3 AEs. 43% of the patients displayed regression, while another 43% had stable disease. Of note, median overall survival of the patients that were vaccine responders was significantly higher than of non-responders (16.8 vs 11.2 months, respectively). In the NCT02426892 phase II study (completed in 2021), 24 HPV16+ incurable HNSCC or anogenital cancer patients were treated with ISA101 and nivolumab (anti-PD1). 8.3% of the 24 patients exhibited a complete response after 3 years, and the overall survival reached 12.5% in the same timeframe67,68. The vaccine is currently still being tested in HPV+ OPSCC patients in combination with pembrolizumab (anti-PD1) and cisplatin in the phase II HCC 19-082 study. Two additional phase II studies were recently published, where ISA101b was combined with the anti-PD1 agent cemiplimab in HPV16+ recurrent/metastatic oropharyngeal cancer (NCT0366971869), and cervical cancer (NCT0464600570), respectively. In the case of oropharyngeal cancer, the combination led to an overall response rate of 25.3% (versus 22.9% in the anti-PD1 monotherapy arm). In cervical cancer, the overall response rate reached 16.8%. However, a more detailed analysis of the cervical cancer trial revealed that the PD-L1+ patients were the ones benefitting the most from the combination (patients with at least 1% PD-L1 expression displayed a 24.1% response rate, while those with less than 1% reached 15.8% overall response rate).CUE-101, which is specific for HPV16 E711-20, a short peptide restricted by HLA-A2, is currently being assessed in an active phase I trial on HPV16+ recurrent/metastatic HNSCC (CUE-101-0171). The vaccine was either tested as monotherapy or in combination with pembrolizumab (anti-PD1). 8% of the patients displayed grade ≥3 AEs during the dose escalation part of the trial, and no significant safety concern arose from the pembrolizumab combination. Among the 19 evaluable patients that received the combination of CUE-101 and pembrolizumab, 47% showed overall response, with two cases of complete response (https://cuebiopharma.gcs-web.com/news-releases/news-release-details/cue-biopharma-reports-new-complete-response-and-confirmed-50). The median progression-free survival (in the combination treatment group) reached 5.8 months. A phase II trial (NCT04852328) is currently recruiting HPV16+ OPSCC patients. In this study, CUE-101 is combined with standard of care treatment. Out of the 20 patients evaluable to date, only one patient experienced grade ≥3 AEs72.PepCan targets the HPV16 E6 protein, divided in four long peptides (cf. Table 1). This vaccine contains Candida albicans skin test reagent (Candin) as an adjuvant. Although in the context of precursor lesions, the Candin adjuvant has proven to be more efficient alone than the vaccine itself and is currently pursued as such73, PepCan is still actively followed in the context of advanced cancers. It was recently given to HNSCC patients in remission in a phase I/II trial (NCT03821272). There, 41.7% of the 12 vaccinated patients had experienced cancer recurrence 24 months post-treatment. Meanwhile, recurrence had occurred in 80% of the 5 placebo-treated patients at the same timepoint74.Viral vector vaccinesTG4001 and PRGN-2009 are both based on viral vectors. TG4001, based on Modified Vaccinia Ankara virus, targets HPV16 E6/E7. In the TG4001.12 phase I/II study, TG4001 was tested in combination with the anti-PD-L1 agent avelumab in HPV16+ recurrent/metastatic anogenital cancer patients75. 2.3% of patients experienced serious AEs, none of them being related to the vaccine. Upon evaluation of 36 patients, an overall response rate of 22% was recorded, including one patient with complete response and seven patients with partial response. An update on the second part of the trial was recently published. There, 6.5% of the patients experienced serious treatment-related AEs in the combination treatment group, versus 4.5% in the avelumab monotherapy group. The overall response rate was 15.2% in the combination treatment group and 13.6% in the monotherapy group76. With this data, the study did not meet its primary objective of improvement (https://www.transgene.fr/wp-content/uploads/20241014_TG4001_Phase_II_update_EN.pdf). So far, no further updates on the future of this vaccine have been released.PRGN-2009 uses GC46 gorilla adenovirus as a vector and targets 35 non-HLA restricted CTL epitopes of HPV16 E5/E6/E7 and HPV18 E6/E7. PRGN-2009 entered a phase I/II trial for the treatment of various HPV+ advanced/metastatic cancers, with or without the PD-L1- and TGFβ-targeting protein bintrafusp alfa77. 27% of patients in the latter group experienced grade ≥3 AEs, while none of the patients receiving the vaccine monotherapy experienced any. None of the 6 patients in the monotherapy arm showed any objective response, whereas the combination with bintrafusp alfa achieved a 20% objective response rate in 10 assessed patients with one complete response and one confirmed partial response. Three further trials are presently active (NCT0599652378) or recruiting for treatment of OPSCC and recurrent/metastatic cervical cancer (NCT0622356879, NCT0615715180).Table 3Therapeutic HPV vaccines actively followed in clinical trials for treatment of advanced cancerVaccineTrial phaseIndicationCombination treatmentTrial typeTrial statusAcronym/IdentifierOutcome/ EfficacyRef.pNGVL4a-CRT/E7 (Detox)IHPV16+ HNSCCCyclophosphamideNon-randomizedopen-label,no control groupTerminated (due to lack of funding)J11129(NCT01493154)N/A-pBI-11(PVX-8)IIhrHPV+PD-L1+ recurrent/ metastatic OPSCCTA-HPV (combination treatment“PVX-7”) + Pembrolizumab (anti-PD1)Open-label,no control groupRecruitingVICCHN2208(NCT05799144)N/A53pBI-11(PVX-8)IAdvanced cervical cancerTA-HPV (combination treatment“PVX-7”)Randomized, open-label,no control groupRecruitingJ23105sIRB(NCT06315257)N/A-GX-188EI/IIHPV16/18+ recurrent/ metastatic cervical cancerPembrolizumabOpen-label,no control groupCompleted in 2023GX-188E-005(NCT03444376)60 patientsa.6.2% of patients with grade ≥3 AEs.Overall response rate (week 24): 35%.Complete response (week 24): 8.3%.54IIHPV16/18+ advanced, resectable HNSCCPembrolizumab + GX-I7 (long-lasting IL-7) post surgeryRandomized, open-label,no control groupRecruitingGENUINE(NCT05286060)11 patientsa (in highest dose cohort).Major pathologic responseb: 63.6%.Complete response: 36.3%.55IIHPV16/18+ recurrent/ metastatic HNSCCNivolumab (anti-PD1) + GX-I7Open-label,no control groupRecruitingTRINITY(NCT05280457)N/A-VB10.16IIHPV16+ recurrent/ metastatic cervical cancerAtezolizumab (anti-PD-L1)Open-label,no control groupCompleted in 2023VB C-02(NCT04405349)47 patientsa.10% of patients with grade ≥3 AEs.Overall response rate (one year): 19.1%.Complete response as best overall response (one year): 6.4%.56I/IIHPV16+ PD-L1+ recurrent/ metastatic OPSCCPembrolizumabNon-randomizedc, open-label,no control groupRecruitingVB-C-03(NCT06016920)N/A57IIHPV16+ PD-L1+ recurrent/ metastatic cervical cancerAtezolizumabRandomized, quadruple-blind,no control groupWithdrawn (due to company strategic reasons)VB-C-04(NCT06099418)N/A-INO-3112IIHPV16+ OPSCCDurvalumab (anti-PD-L1)Randomized, open-label,active controlWithdrawn (funding reasons)NCT04001413N/A-Ib/IIaHPV16/18+ recurrent/metastatic HNSCCDurvalumabOpen-label,no control groupCompleted in 2021NCT0316222429 patientsa.40% of patients with grade ≥3 AEsd.Disease control rate (week 16): 44.8%dOverall response rate (45 months): 27.6%d58IIHPV16/18+ recurrent/metastatic cancersDurvalumabOpen-label,no control groupTerminated (project delayed)NCT0343908521 patients.4.8% of patients with grade ≥3 AEs.Disease control rate (up to two years): 37%.Overall response rate (up to two years): 21%.59BNT113I/IIHPV16+ recurrent HNSCC or anogenital cancer-Open-label,no control groupCompleted in 2024HARE-40(NCT03418480)17 patients with resected HPV16+ HNSCC, disease-free (Arm 1 A) and 13 patients with HPV16+ cancers (Arm 1B).24% of patients with grade ≥3 adverse drug reactionsDisease control ratee (Arm 1B): 71%.60II/IIIHPV16+ PD-L1+ recurrent/ metastatic HNSCCPembrolizumabRandomized, open-label,active controlRecruitingAHEAD-MERIT(NCT04534205)15 patients (in safety run in combination treatment group).26.7%d of patients with grade ≥3 AEs.Disease control rate (up to 48 months): 53%Overall response rate (up to 48 months): 40%.Complete response (up to 48 months): 26.7%d.61CD40HVacI/IIHPV16+ OPSCC-Randomized, double-blind, placebo-controlledRecruitingHPVDCVax(NCT06007092)12 patients (in lowest dose cohort).No patients with grade ≥3 AEs.62PDS0101I/IIVarious HPV+ advanced/ metastatic cancersM7824 (anti-PD-L1/TGFβ fusion protein) + NHS-IL12Open-label,no control groupActive20-C-0045(NCT04287868)50 patients.52% of patients with grade ≥3 AEs.Disease control rate: 34%Overall response rate: 22%.Complete response: 8%.148IIAdvanced cervical cancerRadiation therapy + cisplatinOpen-label,no control groupActiveIMMUNOCERV(NCT04580771)17 patients.47% of patients with grade ≥3 AEs.Reduction of gross tumor volume >90% (5 weeks \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\pm$$\end{document}± 5 days): 29%.Complete metabolic response (24 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\pm$$\end{document}± 2 weeks): 59%.65IIHPV16+ PD-L1+ recurrent/ metastatic HNSCCPembrolizumabOpen-label,no control groupCompleted in 2025VERSATILE-002(NCT04260126)53 patientsd.13% of patients with grade ≥3 AEs.Overall response rate: 34%.Complete response: 7.5%d.63I/IIhrHPV+ advanced OPSCCPembrolizumabRandomized, single-blind,no control groupActiveMC200710(NCT05232851)10 patients (vaccine) vs 10 patients (vaccine + pembrolizumab).5% of patients with grade ≥3 AEs.Disease control rate: 70%d (vaccine) vs 100%d (vaccine + pembrolizumab)Overall response rate: 0% (vaccine) vs 20% (vaccine + pembrolizumab)Complete response: 0% for both groups64IIIHPV16+ PD-L1+ recurrent/ metastatic HNSCCPembrolizumabRandomized, open-label,active controlActiveVERSATILE-003(NCT06790966)N/A-ISA101/ ISA101bI/IIHPV16+ recurrent/ metastatic cervical cancerCarboplatin, paclitaxel, bevacizumab, IFNαNon-randomizedc,open-label,no control groupCompleted in 2018ISA-HPV-01-12(NCT02128126)72 patients (6–14 patients per treatment group).27.8% of patients with grade ≥3 AEs.Disease control rate: 86%.Overall response rate: 43%.Complete response: 5.6%.66IIHPV16+ incurable OPSCCUtomilumabOpen-label,no control groupTerminated (due to slow accrual)2017-0145(NCT03258008)N/A-IIHPV16+ incurrable HNSCC or anogenital cancerNivolumabOpen-label,no control groupCompleted in 20212014-1047(NCT02426892)24 patients.8.3% grade ≥3 AEs.Overall response rate (4.5 years): 33.3%d.Complete response (4.5 years): 8.3%.67,68IIHPV+ OPSCCPembrolizumab, cisplatinOpen-label,no control groupActiveHCC 19-082(NCT04369937)N/A-IIHPV16+ recurrent/ metastatic oropharyngeal cancerCemiplimab (anti-PD1)Randomized, triple-blind,active controlActiveNCT0366971891 patients (vaccine + cemiplimab)a vs 96 patients (cemiplimab only)a48% (vaccine + cemiplimab) vs 44.9% (cemiplimab only) of patients with grade ≥3 AEs.Overall response rate: 25.3% (vaccine + cemplimab) vs 22.9% (cemiplimab only).69IIHPV16+ recurrent/ metastatic cervical cancerCemiplimabOpen-label,no control groupCompleted in 2018NCT04646005113 patients.30.1% of patients with grade ≥3 AEs.Overall response: 16.8%.Complete response as best overall response: 2.7%.70CUE-101IHPV16+ recurrent/ metastatic HNSCCPembrolizumabNon-randomized,open-label,no control groupActiveCUE-101-01(NCT03978689)19 patientsa (vaccine) vs 19 patientsa (vaccine + pembrolizumab).8% of patients with grade ≥3 AEs.Disease control rate: 37% (vaccine) vs 74% (vaccine + pembrolizumab)Overall response rate: 5.3%d (vaccine) vs 47% (vaccine + pembrolizumab).Complete response: 0% (vaccine) vs 5.3%d (vaccine + pembrolizumab).71IIHPV16+ OPSCCStandard of careNon-randomized,open-label,no control groupRecruitingNCT0485232820 patients (10 patients per treatment group).5% of patients with grade ≥3 AEs.72PepCanI/IIPatients in remission of HNSCC-Randomized, double-blind, placebo controlCompleted in 2025217672(NCT03821272)12 patients (vaccine) vs 5 patients (placebo).Cancer recurrence rate (24 months): 41.7% (vaccine) vs 80% (placebo).74TG4001I/IIHPV16+ recurrent/ metastatic anogenital cancerAvelumabRandomized, open-label,active controlActiveTG4001.12(NCT03260023)Phase Ib: 36 patientsa (vaccine + avelumab).2.3% of patients with ≥ grade 3 AEs.Disease control rate: 42%Overall response rate: 22%.Complete response: 2.8%.Phase II: 46 patients (vaccine + avelumab) vs 44 patients (avelumab only).6.5% (vaccine + avelumab) vs 4.5% (avelumab only) of patients with grade ≥3 AEs.Overall response rate: 15.2% (vaccine + avelumab) vs 13.6% (avelumab only).75,76PRGN-2009I/IIVarious HPV+ advanced/ metastatic cancersBintrafusp alphaNon-randomized, open-label,no control groupActive200104(NCT04432597)6 patients (vaccine) vs 10 patientsa (vaccine + bintrafusp alpha).no patients with grade ≥3 AEs (vaccine) vs 27% of patients with grade ≥3 AEs (vaccine + bintrafusp).Disease control rate: 67%d (vaccine) vs 40%d (vaccine + bintrafusp)Overall response rate: 0% (vaccine) vs 20% (vaccine + bintrafusp).Complete response: 0% (vaccine) vs 10% (vaccine + bintrafusp).77IIHPV+ stage I-III OPSCCPembrolizumabOpen-label,no control groupActive10001536(NCT05996523)N/A78IIhrHPV+ stage I or II OPSCCDocetaxel + cisplatinRandomized, open-label,active controlRecruiting10001730(NCT06223568)N/A79IIHPV16/18+ PD-L1+ recurrent/ metastatic cervical cancerPembrolizumabRandomized, open-label,active controlRecruitingPRGN-2009-201(NCT06157151)N/A80aNumber of patients refers to the number of patients analyzed regarding vaccine efficacy in the study.bDefined as residual viable tumor of less than or equal to 10%.cNo randomization for dose escalation phase (phase 1), but randomization during dose expansion phase (phase 2).dValue was calculated by the authors using the available data.eAssessed in 7 patients by post-treatment tumor scans. DNA vaccinesTwo trials are currently ongoing with the pNGVL4a-Hsp70 construct pBI-11 (PVX-8, targeting HVP16/18 E6/E7), combining it with the viral vector-based HPV16/18 E6/E7 vaccine TA-HPV (combination treatment PVX-7) in the context of hrHPV+ PD-L1+ recurrent/metastatic oropharyngeal squamous cell carcinoma (NCT05799144, phase II, recruiting53) and advanced cervical cancer (NCT06315257, phase I, recruiting).GX-188E is a DNA vaccine targeting HPV16 E6/E7 and HPV18 E6/E7, which was recently tested in a phase I/II trial in combination with pembrolizumab (anti-PD1) in HPV16/18+ recurrent/metastatic cervical cancer (GX-188E-00554). At week 24, 35% of the 60 patients showcased an overall response, including 8.3% complete responses. The combination treatment was more successful in PD-L1+ than PD-L1− patients (38.9% vs 29.2% overall response rate). Two phase II trials are currently testing the combination of GX-188E with GX-I7 (a long-acting IL-7) and the anti-PD1 agents pembrolizumab (GENUINE55), or nivolumab (TRINITY), respectively. The GENUINE trial preliminary results showed major pathologic response in 63.6% of HPV16/18+ advanced, resectable head and neck squamous cell carcinoma and a complete response in 36.3% of patients.The DNA vaccine VB10.16 targets HPV16 E6/E7, and its efficacy was assessed in a phase II trial in combination with atezolizumab (anti-PD-L1) in HPV16+ recurrent/metastatic cervical cancer patients (VB-C-02). An overall response rate of 19.1% was achieved after 1 year, including 6.4% complete responses56. Another phase I/II trial (VB-C-03) is currently recruiting to test VB10.16 in HPV16+ PD-L1+ recurrent/metastatic oropharyngeal cancer patients, in combination with pembrolizumab57, while a phase II trial (VB-C-04) in HPV16+ PD-L1+ recurrent/metastatic cervical cancer was withdrawn due to strategic reasons, as announced in a press release in August 2024 (https://nykode.com/wp-content/uploads/2024/08/240821_VB1016-strategic-repositioning-PR-FINAL.pdf).INO-3112, also called MEDI0457, another DNA vaccine, associates VGX-3100 (encoding HPV16/18 E6/E7, cf. precursor lesions) with another DNA vector (INO-9012) encoding for IL-12. It entered three clinical trials for HPV-driven head and neck cancers (NCT04001413, NCT0316224, NCT03439085), all combining the vaccine with the PD-L1 inhibitor durvalumab. NCT04001413 was withdrawn due to funding reasons. In the phase Ib/IIa trial (NCT03162224), completed in 2021, a disease control rate of 44.8% and an overall response rate of 27.6% was observed58. In another phase II trial (NCT03439085)59, similar results were achieved, with a disease control rate of 37% and an overall response rate of 21%. The company announced its intention to soon launch a phase III trial where INO-3112 will be combined with an anti-PD1 agent (toripalimab-tpzi) in HPV16/18+ patients with locally advanced OPSCC (https://ir.inovio.com/news-releases/news-releases-details/2025/INOVIO-Highlights-Anticipated-2025-Milestones-and-2024-Key-Accomplishments/default.aspx). DNA vaccines Two trials are currently ongoing with the pNGVL4a-Hsp70 construct pBI-11 (PVX-8, targeting HVP16/18 E6/E7), combining it with the viral vector-based HPV16/18 E6/E7 vaccine TA-HPV (combination treatment PVX-7) in the context of hrHPV+ PD-L1+ recurrent/metastatic oropharyngeal squamous cell carcinoma (NCT05799144, phase II, recruiting53) and advanced cervical cancer (NCT06315257, phase I, recruiting). GX-188E is a DNA vaccine targeting HPV16 E6/E7 and HPV18 E6/E7, which was recently tested in a phase I/II trial in combination with pembrolizumab (anti-PD1) in HPV16/18+ recurrent/metastatic cervical cancer (GX-188E-00554). At week 24, 35% of the 60 patients showcased an overall response, including 8.3% complete responses. The combination treatment was more successful in PD-L1+ than PD-L1− patients (38.9% vs 29.2% overall response rate). Two phase II trials are currently testing the combination of GX-188E with GX-I7 (a long-acting IL-7) and the anti-PD1 agents pembrolizumab (GENUINE55), or nivolumab (TRINITY), respectively. The GENUINE trial preliminary results showed major pathologic response in 63.6% of HPV16/18+ advanced, resectable head and neck squamous cell carcinoma and a complete response in 36.3% of patients. The DNA vaccine VB10.16 targets HPV16 E6/E7, and its efficacy was assessed in a phase II trial in combination with atezolizumab (anti-PD-L1) in HPV16+ recurrent/metastatic cervical cancer patients (VB-C-02). An overall response rate of 19.1% was achieved after 1 year, including 6.4% complete responses56. Another phase I/II trial (VB-C-03) is currently recruiting to test VB10.16 in HPV16+ PD-L1+ recurrent/metastatic oropharyngeal cancer patients, in combination with pembrolizumab57, while a phase II trial (VB-C-04) in HPV16+ PD-L1+ recurrent/metastatic cervical cancer was withdrawn due to strategic reasons, as announced in a press release in August 2024 (https://nykode.com/wp-content/uploads/2024/08/240821_VB1016-strategic-repositioning-PR-FINAL.pdf). INO-3112, also called MEDI0457, another DNA vaccine, associates VGX-3100 (encoding HPV16/18 E6/E7, cf. precursor lesions) with another DNA vector (INO-9012) encoding for IL-12. It entered three clinical trials for HPV-driven head and neck cancers (NCT04001413, NCT0316224, NCT03439085), all combining the vaccine with the PD-L1 inhibitor durvalumab. NCT04001413 was withdrawn due to funding reasons. In the phase Ib/IIa trial (NCT03162224), completed in 2021, a disease control rate of 44.8% and an overall response rate of 27.6% was observed58. In another phase II trial (NCT03439085)59, similar results were achieved, with a disease control rate of 37% and an overall response rate of 21%. The company announced its intention to soon launch a phase III trial where INO-3112 will be combined with an anti-PD1 agent (toripalimab-tpzi) in HPV16/18+ patients with locally advanced OPSCC (https://ir.inovio.com/news-releases/news-releases-details/2025/INOVIO-Highlights-Anticipated-2025-Milestones-and-2024-Key-Accomplishments/default.aspx). mRNA vaccineBNT113 is an mRNA vaccine specific for HPV16 E6/E7. In the phase I/II HARE-40 trial, completed in 2024, BNT113 was tested in 17 HPV16+ disease-free HNSCC patients (Arm 1A) and in 13 HPV16+ cancer patients (Arm 1B)60. Grade ≥3 adverse drug reactions were observed in 24% of patients, and specific immune responses were detected in both study arms. 71% of 7 patients in Arm 1B, that were evaluated with post-treatment tumor scans, achieved disease control. BNT113 is currently being further explored in combination with pembrolizumab in a phase II/III study on HPV16+ PD-L1+ recurrent/metastatic HNSCC (AHEAD-MERIT61). So far, 26.7% of patients experienced grade ≥3 AEs. The overall response rate was 40% (up to 48 months), and 4 out of 15 patients achieved complete response. mRNA vaccine BNT113 is an mRNA vaccine specific for HPV16 E6/E7. In the phase I/II HARE-40 trial, completed in 2024, BNT113 was tested in 17 HPV16+ disease-free HNSCC patients (Arm 1A) and in 13 HPV16+ cancer patients (Arm 1B)60. Grade ≥3 adverse drug reactions were observed in 24% of patients, and specific immune responses were detected in both study arms. 71% of 7 patients in Arm 1B, that were evaluated with post-treatment tumor scans, achieved disease control. BNT113 is currently being further explored in combination with pembrolizumab in a phase II/III study on HPV16+ PD-L1+ recurrent/metastatic HNSCC (AHEAD-MERIT61). So far, 26.7% of patients experienced grade ≥3 AEs. The overall response rate was 40% (up to 48 months), and 4 out of 15 patients achieved complete response. Protein- and peptide-based vaccinesCD40HVac is a protein-based vaccine, while PDS0101, ISA101(b), CUE-101, and PepCan are all peptide-based vaccines.CD40HVac contains a fusion of HPV16 E6/E7 proteins and an anti-CD40 monoclonal antibody. The HPVDCVax phase I/II study is currently recruiting HPV16+ OPSCC patients to test the vaccine, adjuvanted by poly-ICLC. So far, 12 patients have been recruited for the lowest dose cohort (HPVDCVax), and preliminary results of this cohort indicate a good safety profile of the vaccine62. A phase IIb trial for HPV16+ OPSCC patients is already planned (https://www.biospace.com/press-releases/ennodc-unveils-the-next-generation-of-dendritic-cell-targeting-immunotherapies-supported-by-new-leadership-and-an-evolved-strategy).PDS0101, a vaccine consisting of six HPV16 E6/E7 synthetic long peptides, encapsulated in cationic lipid nanoparticles, has been and is currently being tested in multiple phase I/II and phase II trials (20-C-0045, IMMUNOCERV, VERSATILE-002, MC200710). A first phase III trial (VERSATILE-003) is currently ongoing. In the VERSATILE-002 phase II study (completed in 2025), PDS0101 was administered to HPV16+ PD-L1+ recurrent/metastatic HNSCC patients in combination with pembrolizumab63. The vaccine was well tolerated, with 13% of patients experiencing grade ≥3 AEs. 34% of patients displayed an overall response, including 7.5% exhibiting a complete response, with a median overall survival of 30 months. A recent press release underlined encouraging results for the low PD-L1-expressing population (https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/132-2025-news/1018-pds-biotech-sets-significant-benchmark-in-head-and-neck-canc2025-09-18-055003), which is especially hard to treat with conventional therapy. In the MC200710 phase I/II study, PDS0101 was also tested alone or in combination with pembrolizumab in patients with hrHPV+ advanced OPSCC64. While the overall response rate was 20% in the combination treatment group and 0% in the monotherapy group, high disease control rates of 70% and 100%, respectively, were observed. In the IMMUNOCERV study testing PDS0101 in combination with radiotherapy and cisplatin in advanced cervical cancer patients, 47% of patients experienced grade ≥3 AEs, 29% displayed over 90% gross tumor volume reduction at day 35 and 59% reached complete metabolic response by positron emission tomography computed tomography (PET CT)65.ISA101 and ISA101b, vaccines consisting of HPV16 E6/E7 synthetic long peptides, completed several phase I/II and phase II trials. While the E6 SLPs contained in ISA101 and ISA101b are identical, ISA101b contains three E7 SLPs, while ISA101 contains four, in this way covering seven more amino acids (c.f. Table 1). In the ISA-HPV-01-12 phase I/II trial (completed in 2018), the response to ISA101b compared to ISA101 was assessed with different doses alone or in combination with chemotherapy and IFNα in a total of 72 HPV16+ recurrent/metastatic cervical cancer patients66. Overall, 27.8% of patients experienced grade ≥3 AEs. 43% of the patients displayed regression, while another 43% had stable disease. Of note, median overall survival of the patients that were vaccine responders was significantly higher than of non-responders (16.8 vs 11.2 months, respectively). In the NCT02426892 phase II study (completed in 2021), 24 HPV16+ incurable HNSCC or anogenital cancer patients were treated with ISA101 and nivolumab (anti-PD1). 8.3% of the 24 patients exhibited a complete response after 3 years, and the overall survival reached 12.5% in the same timeframe67,68. The vaccine is currently still being tested in HPV+ OPSCC patients in combination with pembrolizumab (anti-PD1) and cisplatin in the phase II HCC 19-082 study. Two additional phase II studies were recently published, where ISA101b was combined with the anti-PD1 agent cemiplimab in HPV16+ recurrent/metastatic oropharyngeal cancer (NCT0366971869), and cervical cancer (NCT0464600570), respectively. In the case of oropharyngeal cancer, the combination led to an overall response rate of 25.3% (versus 22.9% in the anti-PD1 monotherapy arm). In cervical cancer, the overall response rate reached 16.8%. However, a more detailed analysis of the cervical cancer trial revealed that the PD-L1+ patients were the ones benefitting the most from the combination (patients with at least 1% PD-L1 expression displayed a 24.1% response rate, while those with less than 1% reached 15.8% overall response rate).CUE-101, which is specific for HPV16 E711-20, a short peptide restricted by HLA-A2, is currently being assessed in an active phase I trial on HPV16+ recurrent/metastatic HNSCC (CUE-101-0171). The vaccine was either tested as monotherapy or in combination with pembrolizumab (anti-PD1). 8% of the patients displayed grade ≥3 AEs during the dose escalation part of the trial, and no significant safety concern arose from the pembrolizumab combination. Among the 19 evaluable patients that received the combination of CUE-101 and pembrolizumab, 47% showed overall response, with two cases of complete response (https://cuebiopharma.gcs-web.com/news-releases/news-release-details/cue-biopharma-reports-new-complete-response-and-confirmed-50). The median progression-free survival (in the combination treatment group) reached 5.8 months. A phase II trial (NCT04852328) is currently recruiting HPV16+ OPSCC patients. In this study, CUE-101 is combined with standard of care treatment. Out of the 20 patients evaluable to date, only one patient experienced grade ≥3 AEs72.PepCan targets the HPV16 E6 protein, divided in four long peptides (cf. Table 1). This vaccine contains Candida albicans skin test reagent (Candin) as an adjuvant. Although in the context of precursor lesions, the Candin adjuvant has proven to be more efficient alone than the vaccine itself and is currently pursued as such73, PepCan is still actively followed in the context of advanced cancers. It was recently given to HNSCC patients in remission in a phase I/II trial (NCT03821272). There, 41.7% of the 12 vaccinated patients had experienced cancer recurrence 24 months post-treatment. Meanwhile, recurrence had occurred in 80% of the 5 placebo-treated patients at the same timepoint74. Protein- and peptide-based vaccines CD40HVac is a protein-based vaccine, while PDS0101, ISA101(b), CUE-101, and PepCan are all peptide-based vaccines. CD40HVac contains a fusion of HPV16 E6/E7 proteins and an anti-CD40 monoclonal antibody. The HPVDCVax phase I/II study is currently recruiting HPV16+ OPSCC patients to test the vaccine, adjuvanted by poly-ICLC. So far, 12 patients have been recruited for the lowest dose cohort (HPVDCVax), and preliminary results of this cohort indicate a good safety profile of the vaccine62. A phase IIb trial for HPV16+ OPSCC patients is already planned (https://www.biospace.com/press-releases/ennodc-unveils-the-next-generation-of-dendritic-cell-targeting-immunotherapies-supported-by-new-leadership-and-an-evolved-strategy). PDS0101, a vaccine consisting of six HPV16 E6/E7 synthetic long peptides, encapsulated in cationic lipid nanoparticles, has been and is currently being tested in multiple phase I/II and phase II trials (20-C-0045, IMMUNOCERV, VERSATILE-002, MC200710). A first phase III trial (VERSATILE-003) is currently ongoing. In the VERSATILE-002 phase II study (completed in 2025), PDS0101 was administered to HPV16+ PD-L1+ recurrent/metastatic HNSCC patients in combination with pembrolizumab63. The vaccine was well tolerated, with 13% of patients experiencing grade ≥3 AEs. 34% of patients displayed an overall response, including 7.5% exhibiting a complete response, with a median overall survival of 30 months. A recent press release underlined encouraging results for the low PD-L1-expressing population (https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/132-2025-news/1018-pds-biotech-sets-significant-benchmark-in-head-and-neck-canc2025-09-18-055003), which is especially hard to treat with conventional therapy. In the MC200710 phase I/II study, PDS0101 was also tested alone or in combination with pembrolizumab in patients with hrHPV+ advanced OPSCC64. While the overall response rate was 20% in the combination treatment group and 0% in the monotherapy group, high disease control rates of 70% and 100%, respectively, were observed. In the IMMUNOCERV study testing PDS0101 in combination with radiotherapy and cisplatin in advanced cervical cancer patients, 47% of patients experienced grade ≥3 AEs, 29% displayed over 90% gross tumor volume reduction at day 35 and 59% reached complete metabolic response by positron emission tomography computed tomography (PET CT)65. ISA101 and ISA101b, vaccines consisting of HPV16 E6/E7 synthetic long peptides, completed several phase I/II and phase II trials. While the E6 SLPs contained in ISA101 and ISA101b are identical, ISA101b contains three E7 SLPs, while ISA101 contains four, in this way covering seven more amino acids (c.f. Table 1). In the ISA-HPV-01-12 phase I/II trial (completed in 2018), the response to ISA101b compared to ISA101 was assessed with different doses alone or in combination with chemotherapy and IFNα in a total of 72 HPV16+ recurrent/metastatic cervical cancer patients66. Overall, 27.8% of patients experienced grade ≥3 AEs. 43% of the patients displayed regression, while another 43% had stable disease. Of note, median overall survival of the patients that were vaccine responders was significantly higher than of non-responders (16.8 vs 11.2 months, respectively). In the NCT02426892 phase II study (completed in 2021), 24 HPV16+ incurable HNSCC or anogenital cancer patients were treated with ISA101 and nivolumab (anti-PD1). 8.3% of the 24 patients exhibited a complete response after 3 years, and the overall survival reached 12.5% in the same timeframe67,68. The vaccine is currently still being tested in HPV+ OPSCC patients in combination with pembrolizumab (anti-PD1) and cisplatin in the phase II HCC 19-082 study. Two additional phase II studies were recently published, where ISA101b was combined with the anti-PD1 agent cemiplimab in HPV16+ recurrent/metastatic oropharyngeal cancer (NCT0366971869), and cervical cancer (NCT0464600570), respectively. In the case of oropharyngeal cancer, the combination led to an overall response rate of 25.3% (versus 22.9% in the anti-PD1 monotherapy arm). In cervical cancer, the overall response rate reached 16.8%. However, a more detailed analysis of the cervical cancer trial revealed that the PD-L1+ patients were the ones benefitting the most from the combination (patients with at least 1% PD-L1 expression displayed a 24.1% response rate, while those with less than 1% reached 15.8% overall response rate). CUE-101, which is specific for HPV16 E711-20, a short peptide restricted by HLA-A2, is currently being assessed in an active phase I trial on HPV16+ recurrent/metastatic HNSCC (CUE-101-0171). The vaccine was either tested as monotherapy or in combination with pembrolizumab (anti-PD1). 8% of the patients displayed grade ≥3 AEs during the dose escalation part of the trial, and no significant safety concern arose from the pembrolizumab combination. Among the 19 evaluable patients that received the combination of CUE-101 and pembrolizumab, 47% showed overall response, with two cases of complete response (https://cuebiopharma.gcs-web.com/news-releases/news-release-details/cue-biopharma-reports-new-complete-response-and-confirmed-50). The median progression-free survival (in the combination treatment group) reached 5.8 months. A phase II trial (NCT04852328) is currently recruiting HPV16+ OPSCC patients. In this study, CUE-101 is combined with standard of care treatment. Out of the 20 patients evaluable to date, only one patient experienced grade ≥3 AEs72. PepCan targets the HPV16 E6 protein, divided in four long peptides (cf. Table 1). This vaccine contains Candida albicans skin test reagent (Candin) as an adjuvant. Although in the context of precursor lesions, the Candin adjuvant has proven to be more efficient alone than the vaccine itself and is currently pursued as such73, PepCan is still actively followed in the context of advanced cancers. It was recently given to HNSCC patients in remission in a phase I/II trial (NCT03821272). There, 41.7% of the 12 vaccinated patients had experienced cancer recurrence 24 months post-treatment. Meanwhile, recurrence had occurred in 80% of the 5 placebo-treated patients at the same timepoint74. Viral vector vaccinesTG4001 and PRGN-2009 are both based on viral vectors. TG4001, based on Modified Vaccinia Ankara virus, targets HPV16 E6/E7. In the TG4001.12 phase I/II study, TG4001 was tested in combination with the anti-PD-L1 agent avelumab in HPV16+ recurrent/metastatic anogenital cancer patients75. 2.3% of patients experienced serious AEs, none of them being related to the vaccine. Upon evaluation of 36 patients, an overall response rate of 22% was recorded, including one patient with complete response and seven patients with partial response. An update on the second part of the trial was recently published. There, 6.5% of the patients experienced serious treatment-related AEs in the combination treatment group, versus 4.5% in the avelumab monotherapy group. The overall response rate was 15.2% in the combination treatment group and 13.6% in the monotherapy group76. With this data, the study did not meet its primary objective of improvement (https://www.transgene.fr/wp-content/uploads/20241014_TG4001_Phase_II_update_EN.pdf). So far, no further updates on the future of this vaccine have been released.PRGN-2009 uses GC46 gorilla adenovirus as a vector and targets 35 non-HLA restricted CTL epitopes of HPV16 E5/E6/E7 and HPV18 E6/E7. PRGN-2009 entered a phase I/II trial for the treatment of various HPV+ advanced/metastatic cancers, with or without the PD-L1- and TGFβ-targeting protein bintrafusp alfa77. 27% of patients in the latter group experienced grade ≥3 AEs, while none of the patients receiving the vaccine monotherapy experienced any. None of the 6 patients in the monotherapy arm showed any objective response, whereas the combination with bintrafusp alfa achieved a 20% objective response rate in 10 assessed patients with one complete response and one confirmed partial response. Three further trials are presently active (NCT0599652378) or recruiting for treatment of OPSCC and recurrent/metastatic cervical cancer (NCT0622356879, NCT0615715180). Viral vector vaccines TG4001 and PRGN-2009 are both based on viral vectors. TG4001, based on Modified Vaccinia Ankara virus, targets HPV16 E6/E7. In the TG4001.12 phase I/II study, TG4001 was tested in combination with the anti-PD-L1 agent avelumab in HPV16+ recurrent/metastatic anogenital cancer patients75. 2.3% of patients experienced serious AEs, none of them being related to the vaccine. Upon evaluation of 36 patients, an overall response rate of 22% was recorded, including one patient with complete response and seven patients with partial response. An update on the second part of the trial was recently published. There, 6.5% of the patients experienced serious treatment-related AEs in the combination treatment group, versus 4.5% in the avelumab monotherapy group. The overall response rate was 15.2% in the combination treatment group and 13.6% in the monotherapy group76. With this data, the study did not meet its primary objective of improvement (https://www.transgene.fr/wp-content/uploads/20241014_TG4001_Phase_II_update_EN.pdf). So far, no further updates on the future of this vaccine have been released. PRGN-2009 uses GC46 gorilla adenovirus as a vector and targets 35 non-HLA restricted CTL epitopes of HPV16 E5/E6/E7 and HPV18 E6/E7. PRGN-2009 entered a phase I/II trial for the treatment of various HPV+ advanced/metastatic cancers, with or without the PD-L1- and TGFβ-targeting protein bintrafusp alfa77. 27% of patients in the latter group experienced grade ≥3 AEs, while none of the patients receiving the vaccine monotherapy experienced any. None of the 6 patients in the monotherapy arm showed any objective response, whereas the combination with bintrafusp alfa achieved a 20% objective response rate in 10 assessed patients with one complete response and one confirmed partial response. Three further trials are presently active (NCT0599652378) or recruiting for treatment of OPSCC and recurrent/metastatic cervical cancer (NCT0622356879, NCT0615715180). Table 3Therapeutic HPV vaccines actively followed in clinical trials for treatment of advanced cancerVaccineTrial phaseIndicationCombination treatmentTrial typeTrial statusAcronym/IdentifierOutcome/ EfficacyRef.pNGVL4a-CRT/E7 (Detox)IHPV16+ HNSCCCyclophosphamideNon-randomizedopen-label,no control groupTerminated (due to lack of funding)J11129(NCT01493154)N/A-pBI-11(PVX-8)IIhrHPV+PD-L1+ recurrent/ metastatic OPSCCTA-HPV (combination treatment“PVX-7”) + Pembrolizumab (anti-PD1)Open-label,no control groupRecruitingVICCHN2208(NCT05799144)N/A53pBI-11(PVX-8)IAdvanced cervical cancerTA-HPV (combination treatment“PVX-7”)Randomized, open-label,no control groupRecruitingJ23105sIRB(NCT06315257)N/A-GX-188EI/IIHPV16/18+ recurrent/ metastatic cervical cancerPembrolizumabOpen-label,no control groupCompleted in 2023GX-188E-005(NCT03444376)60 patientsa.6.2% of patients with grade ≥3 AEs.Overall response rate (week 24): 35%.Complete response (week 24): 8.3%.54IIHPV16/18+ advanced, resectable HNSCCPembrolizumab + GX-I7 (long-lasting IL-7) post surgeryRandomized, open-label,no control groupRecruitingGENUINE(NCT05286060)11 patientsa (in highest dose cohort).Major pathologic responseb: 63.6%.Complete response: 36.3%.55IIHPV16/18+ recurrent/ metastatic HNSCCNivolumab (anti-PD1) + GX-I7Open-label,no control groupRecruitingTRINITY(NCT05280457)N/A-VB10.16IIHPV16+ recurrent/ metastatic cervical cancerAtezolizumab (anti-PD-L1)Open-label,no control groupCompleted in 2023VB C-02(NCT04405349)47 patientsa.10% of patients with grade ≥3 AEs.Overall response rate (one year): 19.1%.Complete response as best overall response (one year): 6.4%.56I/IIHPV16+ PD-L1+ recurrent/ metastatic OPSCCPembrolizumabNon-randomizedc, open-label,no control groupRecruitingVB-C-03(NCT06016920)N/A57IIHPV16+ PD-L1+ recurrent/ metastatic cervical cancerAtezolizumabRandomized, quadruple-blind,no control groupWithdrawn (due to company strategic reasons)VB-C-04(NCT06099418)N/A-INO-3112IIHPV16+ OPSCCDurvalumab (anti-PD-L1)Randomized, open-label,active controlWithdrawn (funding reasons)NCT04001413N/A-Ib/IIaHPV16/18+ recurrent/metastatic HNSCCDurvalumabOpen-label,no control groupCompleted in 2021NCT0316222429 patientsa.40% of patients with grade ≥3 AEsd.Disease control rate (week 16): 44.8%dOverall response rate (45 months): 27.6%d58IIHPV16/18+ recurrent/metastatic cancersDurvalumabOpen-label,no control groupTerminated (project delayed)NCT0343908521 patients.4.8% of patients with grade ≥3 AEs.Disease control rate (up to two years): 37%.Overall response rate (up to two years): 21%.59BNT113I/IIHPV16+ recurrent HNSCC or anogenital cancer-Open-label,no control groupCompleted in 2024HARE-40(NCT03418480)17 patients with resected HPV16+ HNSCC, disease-free (Arm 1 A) and 13 patients with HPV16+ cancers (Arm 1B).24% of patients with grade ≥3 adverse drug reactionsDisease control ratee (Arm 1B): 71%.60II/IIIHPV16+ PD-L1+ recurrent/ metastatic HNSCCPembrolizumabRandomized, open-label,active controlRecruitingAHEAD-MERIT(NCT04534205)15 patients (in safety run in combination treatment group).26.7%d of patients with grade ≥3 AEs.Disease control rate (up to 48 months): 53%Overall response rate (up to 48 months): 40%.Complete response (up to 48 months): 26.7%d.61CD40HVacI/IIHPV16+ OPSCC-Randomized, double-blind, placebo-controlledRecruitingHPVDCVax(NCT06007092)12 patients (in lowest dose cohort).No patients with grade ≥3 AEs.62PDS0101I/IIVarious HPV+ advanced/ metastatic cancersM7824 (anti-PD-L1/TGFβ fusion protein) + NHS-IL12Open-label,no control groupActive20-C-0045(NCT04287868)50 patients.52% of patients with grade ≥3 AEs.Disease control rate: 34%Overall response rate: 22%.Complete response: 8%.148IIAdvanced cervical cancerRadiation therapy + cisplatinOpen-label,no control groupActiveIMMUNOCERV(NCT04580771)17 patients.47% of patients with grade ≥3 AEs.Reduction of gross tumor volume >90% (5 weeks \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\pm$$\end{document}± 5 days): 29%.Complete metabolic response (24 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\pm$$\end{document}± 2 weeks): 59%.65IIHPV16+ PD-L1+ recurrent/ metastatic HNSCCPembrolizumabOpen-label,no control groupCompleted in 2025VERSATILE-002(NCT04260126)53 patientsd.13% of patients with grade ≥3 AEs.Overall response rate: 34%.Complete response: 7.5%d.63I/IIhrHPV+ advanced OPSCCPembrolizumabRandomized, single-blind,no control groupActiveMC200710(NCT05232851)10 patients (vaccine) vs 10 patients (vaccine + pembrolizumab).5% of patients with grade ≥3 AEs.Disease control rate: 70%d (vaccine) vs 100%d (vaccine + pembrolizumab)Overall response rate: 0% (vaccine) vs 20% (vaccine + pembrolizumab)Complete response: 0% for both groups64IIIHPV16+ PD-L1+ recurrent/ metastatic HNSCCPembrolizumabRandomized, open-label,active controlActiveVERSATILE-003(NCT06790966)N/A-ISA101/ ISA101bI/IIHPV16+ recurrent/ metastatic cervical cancerCarboplatin, paclitaxel, bevacizumab, IFNαNon-randomizedc,open-label,no control groupCompleted in 2018ISA-HPV-01-12(NCT02128126)72 patients (6–14 patients per treatment group).27.8% of patients with grade ≥3 AEs.Disease control rate: 86%.Overall response rate: 43%.Complete response: 5.6%.66IIHPV16+ incurable OPSCCUtomilumabOpen-label,no control groupTerminated (due to slow accrual)2017-0145(NCT03258008)N/A-IIHPV16+ incurrable HNSCC or anogenital cancerNivolumabOpen-label,no control groupCompleted in 20212014-1047(NCT02426892)24 patients.8.3% grade ≥3 AEs.Overall response rate (4.5 years): 33.3%d.Complete response (4.5 years): 8.3%.67,68IIHPV+ OPSCCPembrolizumab, cisplatinOpen-label,no control groupActiveHCC 19-082(NCT04369937)N/A-IIHPV16+ recurrent/ metastatic oropharyngeal cancerCemiplimab (anti-PD1)Randomized, triple-blind,active controlActiveNCT0366971891 patients (vaccine + cemiplimab)a vs 96 patients (cemiplimab only)a48% (vaccine + cemiplimab) vs 44.9% (cemiplimab only) of patients with grade ≥3 AEs.Overall response rate: 25.3% (vaccine + cemplimab) vs 22.9% (cemiplimab only).69IIHPV16+ recurrent/ metastatic cervical cancerCemiplimabOpen-label,no control groupCompleted in 2018NCT04646005113 patients.30.1% of patients with grade ≥3 AEs.Overall response: 16.8%.Complete response as best overall response: 2.7%.70CUE-101IHPV16+ recurrent/ metastatic HNSCCPembrolizumabNon-randomized,open-label,no control groupActiveCUE-101-01(NCT03978689)19 patientsa (vaccine) vs 19 patientsa (vaccine + pembrolizumab).8% of patients with grade ≥3 AEs.Disease control rate: 37% (vaccine) vs 74% (vaccine + pembrolizumab)Overall response rate: 5.3%d (vaccine) vs 47% (vaccine + pembrolizumab).Complete response: 0% (vaccine) vs 5.3%d (vaccine + pembrolizumab).71IIHPV16+ OPSCCStandard of careNon-randomized,open-label,no control groupRecruitingNCT0485232820 patients (10 patients per treatment group).5% of patients with grade ≥3 AEs.72PepCanI/IIPatients in remission of HNSCC-Randomized, double-blind, placebo controlCompleted in 2025217672(NCT03821272)12 patients (vaccine) vs 5 patients (placebo).Cancer recurrence rate (24 months): 41.7% (vaccine) vs 80% (placebo).74TG4001I/IIHPV16+ recurrent/ metastatic anogenital cancerAvelumabRandomized, open-label,active controlActiveTG4001.12(NCT03260023)Phase Ib: 36 patientsa (vaccine + avelumab).2.3% of patients with ≥ grade 3 AEs.Disease control rate: 42%Overall response rate: 22%.Complete response: 2.8%.Phase II: 46 patients (vaccine + avelumab) vs 44 patients (avelumab only).6.5% (vaccine + avelumab) vs 4.5% (avelumab only) of patients with grade ≥3 AEs.Overall response rate: 15.2% (vaccine + avelumab) vs 13.6% (avelumab only).75,76PRGN-2009I/IIVarious HPV+ advanced/ metastatic cancersBintrafusp alphaNon-randomized, open-label,no control groupActive200104(NCT04432597)6 patients (vaccine) vs 10 patientsa (vaccine + bintrafusp alpha).no patients with grade ≥3 AEs (vaccine) vs 27% of patients with grade ≥3 AEs (vaccine + bintrafusp).Disease control rate: 67%d (vaccine) vs 40%d (vaccine + bintrafusp)Overall response rate: 0% (vaccine) vs 20% (vaccine + bintrafusp).Complete response: 0% (vaccine) vs 10% (vaccine + bintrafusp).77IIHPV+ stage I-III OPSCCPembrolizumabOpen-label,no control groupActive10001536(NCT05996523)N/A78IIhrHPV+ stage I or II OPSCCDocetaxel + cisplatinRandomized, open-label,active controlRecruiting10001730(NCT06223568)N/A79IIHPV16/18+ PD-L1+ recurrent/ metastatic cervical cancerPembrolizumabRandomized, open-label,active controlRecruitingPRGN-2009-201(NCT06157151)N/A80aNumber of patients refers to the number of patients analyzed regarding vaccine efficacy in the study.bDefined as residual viable tumor of less than or equal to 10%.cNo randomization for dose escalation phase (phase 1), but randomization during dose expansion phase (phase 2).dValue was calculated by the authors using the available data.eAssessed in 7 patients by post-treatment tumor scans. Therapeutic HPV vaccines actively followed in clinical trials for treatment of advanced cancer Non-randomized open-label, no control group J11129 (NCT01493154) pBI-11 (PVX-8) hrHPV+ PD-L1+ recurrent/ metastatic OPSCC TA-HPV (combination treatment “PVX-7”) + Pembrolizumab (anti-PD1) Open-label, no control group VICCHN2208 (NCT05799144) pBI-11 (PVX-8) TA-HPV (combination treatment “PVX-7”) Randomized, open-label, no control group J23105sIRB (NCT06315257) Open-label, no control group GX-188E-005 (NCT03444376) 60 patientsa. 6.2% of patients with grade ≥3 AEs. Overall response rate (week 24): 35%. Complete response (week 24): 8.3%. Randomized, open-label, no control group GENUINE (NCT05286060) 11 patientsa (in highest dose cohort). Major pathologic responseb: 63.6%. Complete response: 36.3%. Open-label, no control group TRINITY (NCT05280457) Open-label, no control group VB C-02 (NCT04405349) 47 patientsa. 10% of patients with grade ≥3 AEs. Overall response rate (one year): 19.1%. Complete response as best overall response (one year): 6.4%. Non-randomizedc, open-label, no control group VB-C-03 (NCT06016920) Randomized, quadruple-blind, no control group VB-C-04 (NCT06099418) Randomized, open-label, active control Open-label, no control group 29 patientsa. 40% of patients with grade ≥3 AEsd. Disease control rate (week 16): 44.8%d Overall response rate (45 months): 27.6%d Open-label, no control group 21 patients. 4.8% of patients with grade ≥3 AEs. Disease control rate (up to two years): 37%. Overall response rate (up to two years): 21%. Open-label, no control group HARE-40 (NCT03418480) 17 patients with resected HPV16+ HNSCC, disease-free (Arm 1 A) and 13 patients with HPV16+ cancers (Arm 1B). 24% of patients with grade ≥3 adverse drug reactions Disease control ratee (Arm 1B): 71%. Randomized, open-label, active control AHEAD-MERIT (NCT04534205) 15 patients (in safety run in combination treatment group). 26.7%d of patients with grade ≥3 AEs. Disease control rate (up to 48 months): 53% Overall response rate (up to 48 months): 40%. Complete response (up to 48 months): 26.7%d. HPVDCVax (NCT06007092) 12 patients (in lowest dose cohort). No patients with grade ≥3 AEs. Open-label, no control group 20-C-0045 (NCT04287868) 50 patients. 52% of patients with grade ≥3 AEs. Disease control rate: 34% Overall response rate: 22%. Complete response: 8%. Open-label, no control group IMMUNOCERV (NCT04580771) 17 patients. 47% of patients with grade ≥3 AEs. Reduction of gross tumor volume >90% (5 weeks \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\pm$$\end{document}± 5 days): 29%. Complete metabolic response (24 \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\pm$$\end{document}± 2 weeks): 59%. Open-label, no control group VERSATILE-002 (NCT04260126) 53 patientsd. 13% of patients with grade ≥3 AEs. Overall response rate: 34%. Complete response: 7.5%d. Randomized, single-blind, no control group MC200710 (NCT05232851) 10 patients (vaccine) vs 10 patients (vaccine + pembrolizumab). 5% of patients with grade ≥3 AEs. Disease control rate: 70%d (vaccine) vs 100%d (vaccine + pembrolizumab) Overall response rate: 0% (vaccine) vs 20% (vaccine + pembrolizumab) Complete response: 0% for both groups Randomized, open-label, active control VERSATILE-003 (NCT06790966) Non-randomizedc, open-label, no control group ISA-HPV-01-12 (NCT02128126) 72 patients (6–14 patients per treatment group). 27.8% of patients with grade ≥3 AEs. Disease control rate: 86%. Overall response rate: 43%. Complete response: 5.6%. Open-label, no control group 2017-0145 (NCT03258008) Open-label, no control group 2014-1047 (NCT02426892) 24 patients. 8.3% grade ≥3 AEs. Overall response rate (4.5 years): 33.3%d. Complete response (4.5 years): 8.3%. Open-label, no control group HCC 19-082 (NCT04369937) Randomized, triple-blind, active control 91 patients (vaccine + cemiplimab)a vs 96 patients (cemiplimab only)a 48% (vaccine + cemiplimab) vs 44.9% (cemiplimab only) of patients with grade ≥3 AEs. Overall response rate: 25.3% (vaccine + cemplimab) vs 22.9% (cemiplimab only). Open-label, no control group 113 patients. 30.1% of patients with grade ≥3 AEs. Overall response: 16.8%. Complete response as best overall response: 2.7%. Non-randomized, open-label, no control group CUE-101-01 (NCT03978689) 19 patientsa (vaccine) vs 19 patientsa (vaccine + pembrolizumab). 8% of patients with grade ≥3 AEs. Disease control rate: 37% (vaccine) vs 74% (vaccine + pembrolizumab) Overall response rate: 5.3%d (vaccine) vs 47% (vaccine + pembrolizumab). Complete response: 0% (vaccine) vs 5.3%d (vaccine + pembrolizumab). Non-randomized, open-label, no control group 20 patients (10 patients per treatment group). 5% of patients with grade ≥3 AEs. 217672 (NCT03821272) 12 patients (vaccine) vs 5 patients (placebo). Cancer recurrence rate (24 months): 41.7% (vaccine) vs 80% (placebo). Randomized, open-label, active control TG4001.12 (NCT03260023) Phase Ib: 36 patientsa (vaccine + avelumab). 2.3% of patients with ≥ grade 3 AEs. Disease control rate: 42% Overall response rate: 22%. Complete response: 2.8%. Phase II: 46 patients (vaccine + avelumab) vs 44 patients (avelumab only). 6.5% (vaccine + avelumab) vs 4.5% (avelumab only) of patients with grade ≥3 AEs. Overall response rate: 15.2% (vaccine + avelumab) vs 13.6% (avelumab only). Non-randomized, open-label, no control group 200104 (NCT04432597) 6 patients (vaccine) vs 10 patientsa (vaccine + bintrafusp alpha). no patients with grade ≥3 AEs (vaccine) vs 27% of patients with grade ≥3 AEs (vaccine + bintrafusp). Disease control rate: 67%d (vaccine) vs 40%d (vaccine + bintrafusp) Overall response rate: 0% (vaccine) vs 20% (vaccine + bintrafusp). Complete response: 0% (vaccine) vs 10% (vaccine + bintrafusp). Open-label, no control group 10001536 (NCT05996523) Randomized, open-label, active control 10001730 (NCT06223568) Randomized, open-label, active control PRGN-2009-201 (NCT06157151) aNumber of patients refers to the number of patients analyzed regarding vaccine efficacy in the study. bDefined as residual viable tumor of less than or equal to 10%. cNo randomization for dose escalation phase (phase 1), but randomization during dose expansion phase (phase 2). dValue was calculated by the authors using the available data. eAssessed in 7 patients by post-treatment tumor scans. Vaccine approaches that have reached the clinical stage but are no longer actively followed Multiple therapeutic HPV vaccines have been tested in clinical trials, but are no longer actively followed for various reasons (Table 4).DNA vaccinesThe DNA vaccine ZYC101a/Amolimogene targeting HPV16 E6/E7 and HPV18 E6/E7 was tested until 2009 in a phase II/III trial on CIN2/3 patients (NCT00264732), although no results are available for this study. Another DNA vaccine was tested on high-grade VIN in a phase I/II clinical trial, namely an HPV16 E6/E7 tattoo vaccine81. Most of the AEs observed in this study were mild, although one patient presented a grade 3 AE. Out of five patients in the first cohort, two developed a complete response and one had a partial response. In the second cohort, which included nine patients, only three patients displayed a partial response, while the others did not experience any response. No further updates were released since 2021.Protein- and peptide-based vaccinesSeveral protein vaccines have been tested in various HPV-driven lesions or tumors. SGN-001101/HspE7 targets HPV16 E7 and uses Hsp65 as an adjuvant. In the NCT00052897 phase I/II trial on HIV+ AIN2/3 patients, most adverse events were mild to moderate, although dose-related toxicity was observed. However, after 48 weeks, only 26% of patients regressed to AIN1, while all others were non-responders82. In another phase II trial on CIN3 patients (NCT00075569), 22.5% of the 58 patients achieved a complete response, 55% had a partial response, and 19% had stable disease83. Of note, no differences were observed between women infected by HPV16 or other HPV strains, and it cannot be excluded that the results observed were due to spontaneous regression, as no control arm was included. GTL001/ProCervix targets both HPV16 and HPV18 E7 proteins, and uses a detoxified adenylate cyclase (CyaA) from Bordetella pertussis as an adjuvant. Two trials were started on HPV16/18+ patients with normal cytology or low-grade cervical lesion, a phase I (NCT02689726) and a phase II (NCT01957878) trial. The phase II trial included 47 patients. Adverse events occurred in all patients, among which 17 experienced severe grades. In the open-label portion of the study, 80% of the patients in the 600 µg vaccine/imiquimod combination group responded to the treatment. Similar responses were observed in 62.5% of patients in the placebo/imiquimod group and in 40% of patients in the 100 µg vaccine/imiquimod combination group84. The poor efficacy of this European study led to the termination of the phase I NCT02689726 trial in the US. HPV16 E6E7 ISCOMATRIX consists of a fusion protein of HPV16 E6/E7 and uses Iscomatrix (a component containing cholesterol, phospholipid and saponin85) as an adjuvant. It entered two phase I studies, one for HIV+ hrHPV+ AIN patients86 and one for CIN1/2/3 patients87. Although the vaccine was well tolerated, it showed limited success, with no AIN patients responding and only one CIN2/3 patient regressing to CIN1. PD-E7, another protein vaccine, targets HPV16 E7 and contains AS02B (Haemophilius influenzae protein D) as an adjuvant. In a phase I/II trial on HPV+ CIN1/3 patients, the subjects developed a vaccine-specific response. Nevertheless, the vaccine was not developed further88. Lastly, L1E7-CVLP, a protein vaccine targeting HPV16 E7 and L1, assembling into viral-like particles, was tested in a safety study89. However, no updates were released since 2007.Hespecta consists of two long E6 peptides, HPV16 E671-95 and E6127-158 (also contained in the ISA101 vaccine), which are conjugated to a TLR2 ligand (Amplivant) as an adjuvant. This vaccine was tested in a phase I trial (NCT02821494) on 25 HPV16+ premalignant lesion patients distributed among 4 dose groups. Toxicity was limited to grade 1 or 2 and was dose-dependent. The T cell response measured was also shown to be dose-dependent, with measurable responses only in the highest dose group90. Subsequently, the vaccine was tested in a phase I trial in HPV16 + OSCC patients (NL-OMON41192), but further development was halted. The short peptide vaccine CIGB-228 is specific for the HLA-A2-restricted peptide HPV16 E786-93 and uses very small size proteoliposomes (VSSP) as an adjuvant and delivery platform. It was tested on HPV16+ CIN2/3 and presented a good safety profile (only grade 1 AEs were recorded). Three out of seven patients displayed complete regression and HPV clearance91. However, no further results regarding this vaccine were released since 2011. DPX-E7, which is specific for the HLA-A2-restricted epitope HPV16 E711-19, was administered to HPV16+ recurrent/metastatic OPSCC, cervical or anal cancer patients, either alone or together with cyclophosphamide in a phase I/II study (NCT0286513592). Treatment was well tolerated in the 11 patients. In phase Ib, 16.7% of patients proved to be ELISpot responders, however, there were no responders among the 5 phase II patients. 33.3% phase I patients displayed stable disease. The same proportion was achieved in phase II for the combination therapy group, while all patients in the vaccine monotherapy group experienced disease progression. The vaccine is however, no longer pursued as the company was liquidated. Another peptide vaccine, PCI-E7, using a photochemical internalization technique (NCT0294785493) was tested in a phase I trial on healthy subjects. This vaccine contains two long E7 peptides, HPV16 E71-35 & E762-98. Vaccine doses equal or below 17.5 µg were well tolerated, while doses of 12.5 µg and above induced a specific immune response. However, this vaccine seems to be no longer followed as no update has been published since 2020.Cell-based vaccinesFurthermore, many cell-based vaccines were tested. The BVAC-C vaccine is based on autologous B cells and monocytes loaded with α-galactosyl ceramide and transduced with HPV16 E6/E7 and HPV18 E6/E7. In the BVAC-C-P1 phase I/IIa trial (NCT02866006), although the vaccine was safe, only one out of 26 patients (3.8%) achieved complete response, while 4 patients (15.4%) exhibited partial response94. The subsequent trial for BVAC-C (phase II, NCT04800978) is classified as “unknown status”. Two HPV16/18 E7-pulsed DC-based vaccines were developed by the Universities of Arkansas, USA, and Jena, Germany, respectively, and tested in HPV16/18+ cervical cancer patients, though no objective response was obtained for either of the studies95,96. A variant of the E7-pulsed DC vaccine from the University of Arkansas, containing keyhole limpet hemocyanin (KLH) instead of IL-2, was tested in a phase I trial on cervical cancer patients, where it was found to be safe and immunogenic97. Another autologous monocyte-derived DC-based vaccine was developed by the National Taiwan University Hospital and tested in a phase I trial on HPV16+ cervical cancer (NCT00155766), for which the completion status remains unknown. The trials for SQZ-eAPC-HPV and RTX-321 (both cell-based) were terminated, both because of corporate/sponsor decisions.Viral and bacterial vector vaccinesThe viral vector-based vaccine AD/MG1-E6E7 was tested in a phase Ib trial (NCT03618953) which was terminated due to issues with the vaccine vector. A phase I/II clinical trial (HPV001) for VTP-200 (an adenoviral vector-based vaccine specific for six early proteins of five hrHPV types), involving hr-HPV+ CIN1 patients, was recently completed, and an article is to be released soon (10.1093/cid/ciaf658). However, the Barinthus HPV program was abandoned. The HB-200 vaccine (also called TheraT and Eseba-vec) uses two arenaviruses, namely lymphocytic choriomeningitis virus (LCMV) and pichinde virus (PICV), as vectors, and targets HPV16 E6/E7. HB-200 has been administered in a phase I/II trial in the context of HPV16+ recurrent/metastatic cancers together with the standard of care. Out of 42 patients, 14% experienced grade ≥3 AEs. The overall response rate among the 35 evaluable patients reached 43%, including 3 complete responses and 9 confirmed partial responses98. The developer, Hookipa Pharma, however, recently announced their intention to suspend their activities for financial reasons, and the HPV development program has so far not been taken up by another company. Due to this decision, another trial involving HB-200 for patients with recurrent/metastatic oropharyngeal cancer (NCT06513884) was withdrawn. A Modified Vaccinia Ankara virus-based approach, named MVA-E2, targeting bovine papillomavirus E2 protein, was also tested on CIN2/399 and intraurethral flat condyloma100 patients. As this vaccine does not target human, but bovine papillomavirus, we chose not to include it as HPV vaccine in this review. Besides, no further mention of this approach has been published recently.Lastly, several vaccines based on bacterial vectors were tested in clinical trials, although their development was subsequently stopped. The Listeria monocytogenes-based vaccine ADXS11-001, targeting HPV16 E7, was tested in several trials on HPV16+ cervical cancer, CIN2/3, oropharyngeal cancer, and anal cancer patients. In most of these trials, patients experienced severe adverse events and dose-limiting toxicity. For instance, in the NCT01266460 phase II trial on cervical cancer patients, all of the 50 treated patients experienced AEs, among which 42% were grade 3 or 4. Only one patient had a complete response and two achieved partial response101. This vaccine also entered a phase III trial (NCT02853604) in cervical cancer, but the trial was terminated as none of the 110 patients survived the trial due to disease progression. The NCT01598792 phase I trial on oropharyngeal cancer patients was terminated because a patient suffered dose-limiting toxicity. Both BLS_ILB_E710c and GLBL101c target HPV16 E7 and are based on Lactobacillus casei. Both were tested in HPV16+ CIN3 patients. In the phase I/II trial for BLS_ILB_E710c, no grade 3 or higher AEs were recorded, and 75% of patients experienced clinical efficacy in the phase II part102. However, the absence of a control arm makes it difficult to discriminate the effect of the vaccine from spontaneous regression cases. GLBL101c was well tolerated, with no patients experiencing any serious AEs. 70% of the 10 patients treated with the optimal dose experienced a disease regression to CIN2 at week 9. 5 patients further regressed to LSIL or normal cytology 12 months after the vaccination. However, no follow-up studies were published since 2014103.Table 4Therapeutic HPV vaccines no longer pursuedVaccine nameVaccine typeDeveloperVaccine compositionClinical trialsHPV type and protein/peptide targetedAdjuvant/delivery systemIndicationTrial phaseAcronym/Identifier/Ref.ZYC101a/ AmolimogeneDNAEisai/MGI Pharma BiologicsHPV16 E6/E7 & HPV18 E6/E7poly (D,L-lactide-co-glycolide) microparticlesCIN2/3II/IIIZYC1-004(NCT00264732)HPV16 E6/E7 tattoo vaccineDNANetherlands Cancer InstituteHPV16 E6/E7Epitopes of HIV negative factor protein, P30 epitope from tetanus toxin, pan HLA-DRHPV16+ VIN2/3I/IINTR460781SGN-00101/HspE7ProteinAkela PharmaHPV16 E7Hsp65RRPIISGN-00101-0005(NCT00038714)HIV+ AIN2/3I/IINCI-2012-02507(NCT00052897)82CIN2/3IINCI-3074(NCT00060099)CIN3IINCI-5850(NCT00075569)83HPV16+ CIN3IINCI-2012-02513(NCT00054041)HPV16+ CIN1IINCI-2012-02623(NCT00091130)CIN1-3IHspE7-00101-0601(NCT00493545)GTL001/ProCervixProteinGenticelHPV16 E7 & HPV18 E7CyaAHPV16/18+ normal cytology and CIN1IPC10VAC05(NCT02689726)HPV16/18+ normal cytology and CIN1IIRHEIA-VAC(NCT01957878)84HPV-16 E6E7 ISCOMATRIXProteinUniv. of QueenslandHPV16 E6/E7ISCOMATRIXhrHPV+ HIV+ AIN1-3Ib86CIN1-3I87PD-E7ProteinUniv. of BrusselsHPV16 E7AS02B (Haemophilius influenzae protein D)hrHPV+ CIN1 &HPV16+ CIN3I/II88L1E7 CVLPProteinUniv. of JenaHPV16 E7 & L1Chimeric L1-based virus-like particles (CVLPs)CIN2/3I89Hespecta/ISA201Synthetic long peptidesISA PharmaceuticalsHPV16 E671-95& E6127-158Amplivant (TLR2 ligand)HPV16+ (pre)malignant lesionsI2014-000658-12(NCT02821494)90Treated HPV16+ OSCC patientsINL-OMON41192CIGB-228Short peptideCIGBHPV16 E786-93VSSPHPV16+ CIN2/391DPX-E7Short peptideDana-Farber/ ImmunovaccineHPV16 E711-19, HLA-A2-restrictedOil-based DepoVax (DPX) platformHPV16+ recurrent/ metastatic OPSCC, cervical or anal cancerI/II15-578 (NCT02865135)92PCI-E7Synthetic long peptidesPCI BiotechHPV16 E71-35 & E762-98Fimaporfin; poly-ICLCHealthy volunteersINCT0294785493BVAC-CCell-basedCellidHPV16 E6/E7 & HPV18 E6/E7Autologous B cells and monocytes loaded with α-galactosyl ceramideHPV16/18+ cervical cancerIIESR-18-14325(NCT04800978)HPV16/18+ cervical cancerI/IIBVAC-C-P1(NCT02866006)94E7-pulsed DCsCell-basedUniv. of JenaHPV16 E7 & HPV18 E7Autologous monocyte-derived DCsHPV16/18+ cervical cancer95E7-pulsed DCsCell-basedUniv. of ArkansasHPV16 E7 & HPV18 E7Autologous monocyte-derived DCs; IL-2HPV16/18+ cervical cancer96Autologous monocyte-derived DCs; KLHHPV16/18+ cervical cancerI97DC vaccineCell-basedNational Taiwan University HospitalHPV16 E7 peptidesAutologous PBMC-derived DCsHPV16+ cervical cancerINCT00155766SQZ-eAPC-HPVCell-basedSQZ BiotechnologiesHPV16 E6/E7Autologous PBMCs treated with CD86-, IL-2- and IL-12-encoding mRNAsHPV16+ solid tumorsI/IICOMMANDER-001(NCT05357898)RTX-321Cell-basedRubius TherapeuticsHPV16 E7-derivedHLA-A*02:01-binding peptideEngineered red blood cells expressing 4-1BBL and IL-12HLA-A*02:01+ HPV16+ solid tumorsINCT04672980AD/MG1-E6E7Viral vectorTurnstone BiologicsHPV16 E6/E7 & HPV18 E6/E7MG1 virus and AdenovirusHPV+ solid tumorsIAd-MG1-E6E7-002(NCT03618953)VTP-200Viral vectorVaccitech/Barinthus6 early proteins from 5 hrHPVsChimpanzee Adenovirus (ChAdOx) prime, MVA boosthrHPV+ CIN1I/IIHPV001(NCT04607850)HB-200(HB-201 + HB-202)/Eseba-vec/ TheraT/Viral vectorHookipa PharmaHPV16 E6/E7Lymphocytic choriomeningitis virus (LCMV) and Pichinde virus (PICV)HPV16+ recurrent/ metastatic cancerI/IIH-200-001(NCT04180215)98HPV16+ OPSCCI/IIIRB21-1031(NCT05108870)HPV16+ PD-L1+ recurrent/ metastatic OPSCCII/IIIH-200-004(NCT06513884)ADXS11-001/ Lovaxin C/Lm-LLO-E7Bacterial vectorAdvaxisHPV16 E7Listeria monocytogenes; LLOCIN2/3IILm-LLO-E7-07(NCT01116245)Cervical cancerIINCI-2011-02671(NCT01266460)101HPV16+ OPSCCI2010-019916-20(NCT01598792)Anal cancerI/IIBrUOG 276(NCT01671488)HPV16+ OPSCCIIH-36001 GCO 13-1411(NCT02002182)Cervical cancerILm-LLO-E7-1401(NCT02164461)Cervical cancer or HPV16+ OPSCCI/IIADXS001-04(NCT02291055)Cervical cancerIIIADXS001-02(NCT02853604)Anal cancerIIADXS001-06(NCT02399813)HPV16+ CIN3I/IIUMT2013-BLS-ILB-E710c(NCT02195089)102BLS_ILB_E710cBacterial vectorBioLeadersHPV16 E7Lactobacillus caseiHPV16+ CIN3I/IIa103GLBL101cBacterial vectorGENOLAC BLHPV16 E7Lactobacillus caseiHsp65 Heat shock protein 65, CyaA detoxified adenylate cyclase from Bordetella pertussis, VSSP very small size proteoliposomes, poly-ICLC polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose, KLH Keyhole Limpet Hemocyanin, LLO Listeriolysin O. DNA vaccinesThe DNA vaccine ZYC101a/Amolimogene targeting HPV16 E6/E7 and HPV18 E6/E7 was tested until 2009 in a phase II/III trial on CIN2/3 patients (NCT00264732), although no results are available for this study. Another DNA vaccine was tested on high-grade VIN in a phase I/II clinical trial, namely an HPV16 E6/E7 tattoo vaccine81. Most of the AEs observed in this study were mild, although one patient presented a grade 3 AE. Out of five patients in the first cohort, two developed a complete response and one had a partial response. In the second cohort, which included nine patients, only three patients displayed a partial response, while the others did not experience any response. No further updates were released since 2021. DNA vaccines The DNA vaccine ZYC101a/Amolimogene targeting HPV16 E6/E7 and HPV18 E6/E7 was tested until 2009 in a phase II/III trial on CIN2/3 patients (NCT00264732), although no results are available for this study. Another DNA vaccine was tested on high-grade VIN in a phase I/II clinical trial, namely an HPV16 E6/E7 tattoo vaccine81. Most of the AEs observed in this study were mild, although one patient presented a grade 3 AE. Out of five patients in the first cohort, two developed a complete response and one had a partial response. In the second cohort, which included nine patients, only three patients displayed a partial response, while the others did not experience any response. No further updates were released since 2021. Protein- and peptide-based vaccinesSeveral protein vaccines have been tested in various HPV-driven lesions or tumors. SGN-001101/HspE7 targets HPV16 E7 and uses Hsp65 as an adjuvant. In the NCT00052897 phase I/II trial on HIV+ AIN2/3 patients, most adverse events were mild to moderate, although dose-related toxicity was observed. However, after 48 weeks, only 26% of patients regressed to AIN1, while all others were non-responders82. In another phase II trial on CIN3 patients (NCT00075569), 22.5% of the 58 patients achieved a complete response, 55% had a partial response, and 19% had stable disease83. Of note, no differences were observed between women infected by HPV16 or other HPV strains, and it cannot be excluded that the results observed were due to spontaneous regression, as no control arm was included. GTL001/ProCervix targets both HPV16 and HPV18 E7 proteins, and uses a detoxified adenylate cyclase (CyaA) from Bordetella pertussis as an adjuvant. Two trials were started on HPV16/18+ patients with normal cytology or low-grade cervical lesion, a phase I (NCT02689726) and a phase II (NCT01957878) trial. The phase II trial included 47 patients. Adverse events occurred in all patients, among which 17 experienced severe grades. In the open-label portion of the study, 80% of the patients in the 600 µg vaccine/imiquimod combination group responded to the treatment. Similar responses were observed in 62.5% of patients in the placebo/imiquimod group and in 40% of patients in the 100 µg vaccine/imiquimod combination group84. The poor efficacy of this European study led to the termination of the phase I NCT02689726 trial in the US. HPV16 E6E7 ISCOMATRIX consists of a fusion protein of HPV16 E6/E7 and uses Iscomatrix (a component containing cholesterol, phospholipid and saponin85) as an adjuvant. It entered two phase I studies, one for HIV+ hrHPV+ AIN patients86 and one for CIN1/2/3 patients87. Although the vaccine was well tolerated, it showed limited success, with no AIN patients responding and only one CIN2/3 patient regressing to CIN1. PD-E7, another protein vaccine, targets HPV16 E7 and contains AS02B (Haemophilius influenzae protein D) as an adjuvant. In a phase I/II trial on HPV+ CIN1/3 patients, the subjects developed a vaccine-specific response. Nevertheless, the vaccine was not developed further88. Lastly, L1E7-CVLP, a protein vaccine targeting HPV16 E7 and L1, assembling into viral-like particles, was tested in a safety study89. However, no updates were released since 2007.Hespecta consists of two long E6 peptides, HPV16 E671-95 and E6127-158 (also contained in the ISA101 vaccine), which are conjugated to a TLR2 ligand (Amplivant) as an adjuvant. This vaccine was tested in a phase I trial (NCT02821494) on 25 HPV16+ premalignant lesion patients distributed among 4 dose groups. Toxicity was limited to grade 1 or 2 and was dose-dependent. The T cell response measured was also shown to be dose-dependent, with measurable responses only in the highest dose group90. Subsequently, the vaccine was tested in a phase I trial in HPV16 + OSCC patients (NL-OMON41192), but further development was halted. The short peptide vaccine CIGB-228 is specific for the HLA-A2-restricted peptide HPV16 E786-93 and uses very small size proteoliposomes (VSSP) as an adjuvant and delivery platform. It was tested on HPV16+ CIN2/3 and presented a good safety profile (only grade 1 AEs were recorded). Three out of seven patients displayed complete regression and HPV clearance91. However, no further results regarding this vaccine were released since 2011. DPX-E7, which is specific for the HLA-A2-restricted epitope HPV16 E711-19, was administered to HPV16+ recurrent/metastatic OPSCC, cervical or anal cancer patients, either alone or together with cyclophosphamide in a phase I/II study (NCT0286513592). Treatment was well tolerated in the 11 patients. In phase Ib, 16.7% of patients proved to be ELISpot responders, however, there were no responders among the 5 phase II patients. 33.3% phase I patients displayed stable disease. The same proportion was achieved in phase II for the combination therapy group, while all patients in the vaccine monotherapy group experienced disease progression. The vaccine is however, no longer pursued as the company was liquidated. Another peptide vaccine, PCI-E7, using a photochemical internalization technique (NCT0294785493) was tested in a phase I trial on healthy subjects. This vaccine contains two long E7 peptides, HPV16 E71-35 & E762-98. Vaccine doses equal or below 17.5 µg were well tolerated, while doses of 12.5 µg and above induced a specific immune response. However, this vaccine seems to be no longer followed as no update has been published since 2020. Protein- and peptide-based vaccines Several protein vaccines have been tested in various HPV-driven lesions or tumors. SGN-001101/HspE7 targets HPV16 E7 and uses Hsp65 as an adjuvant. In the NCT00052897 phase I/II trial on HIV+ AIN2/3 patients, most adverse events were mild to moderate, although dose-related toxicity was observed. However, after 48 weeks, only 26% of patients regressed to AIN1, while all others were non-responders82. In another phase II trial on CIN3 patients (NCT00075569), 22.5% of the 58 patients achieved a complete response, 55% had a partial response, and 19% had stable disease83. Of note, no differences were observed between women infected by HPV16 or other HPV strains, and it cannot be excluded that the results observed were due to spontaneous regression, as no control arm was included. GTL001/ProCervix targets both HPV16 and HPV18 E7 proteins, and uses a detoxified adenylate cyclase (CyaA) from Bordetella pertussis as an adjuvant. Two trials were started on HPV16/18+ patients with normal cytology or low-grade cervical lesion, a phase I (NCT02689726) and a phase II (NCT01957878) trial. The phase II trial included 47 patients. Adverse events occurred in all patients, among which 17 experienced severe grades. In the open-label portion of the study, 80% of the patients in the 600 µg vaccine/imiquimod combination group responded to the treatment. Similar responses were observed in 62.5% of patients in the placebo/imiquimod group and in 40% of patients in the 100 µg vaccine/imiquimod combination group84. The poor efficacy of this European study led to the termination of the phase I NCT02689726 trial in the US. HPV16 E6E7 ISCOMATRIX consists of a fusion protein of HPV16 E6/E7 and uses Iscomatrix (a component containing cholesterol, phospholipid and saponin85) as an adjuvant. It entered two phase I studies, one for HIV+ hrHPV+ AIN patients86 and one for CIN1/2/3 patients87. Although the vaccine was well tolerated, it showed limited success, with no AIN patients responding and only one CIN2/3 patient regressing to CIN1. PD-E7, another protein vaccine, targets HPV16 E7 and contains AS02B (Haemophilius influenzae protein D) as an adjuvant. In a phase I/II trial on HPV+ CIN1/3 patients, the subjects developed a vaccine-specific response. Nevertheless, the vaccine was not developed further88. Lastly, L1E7-CVLP, a protein vaccine targeting HPV16 E7 and L1, assembling into viral-like particles, was tested in a safety study89. However, no updates were released since 2007. Hespecta consists of two long E6 peptides, HPV16 E671-95 and E6127-158 (also contained in the ISA101 vaccine), which are conjugated to a TLR2 ligand (Amplivant) as an adjuvant. This vaccine was tested in a phase I trial (NCT02821494) on 25 HPV16+ premalignant lesion patients distributed among 4 dose groups. Toxicity was limited to grade 1 or 2 and was dose-dependent. The T cell response measured was also shown to be dose-dependent, with measurable responses only in the highest dose group90. Subsequently, the vaccine was tested in a phase I trial in HPV16 + OSCC patients (NL-OMON41192), but further development was halted. The short peptide vaccine CIGB-228 is specific for the HLA-A2-restricted peptide HPV16 E786-93 and uses very small size proteoliposomes (VSSP) as an adjuvant and delivery platform. It was tested on HPV16+ CIN2/3 and presented a good safety profile (only grade 1 AEs were recorded). Three out of seven patients displayed complete regression and HPV clearance91. However, no further results regarding this vaccine were released since 2011. DPX-E7, which is specific for the HLA-A2-restricted epitope HPV16 E711-19, was administered to HPV16+ recurrent/metastatic OPSCC, cervical or anal cancer patients, either alone or together with cyclophosphamide in a phase I/II study (NCT0286513592). Treatment was well tolerated in the 11 patients. In phase Ib, 16.7% of patients proved to be ELISpot responders, however, there were no responders among the 5 phase II patients. 33.3% phase I patients displayed stable disease. The same proportion was achieved in phase II for the combination therapy group, while all patients in the vaccine monotherapy group experienced disease progression. The vaccine is however, no longer pursued as the company was liquidated. Another peptide vaccine, PCI-E7, using a photochemical internalization technique (NCT0294785493) was tested in a phase I trial on healthy subjects. This vaccine contains two long E7 peptides, HPV16 E71-35 & E762-98. Vaccine doses equal or below 17.5 µg were well tolerated, while doses of 12.5 µg and above induced a specific immune response. However, this vaccine seems to be no longer followed as no update has been published since 2020. Cell-based vaccinesFurthermore, many cell-based vaccines were tested. The BVAC-C vaccine is based on autologous B cells and monocytes loaded with α-galactosyl ceramide and transduced with HPV16 E6/E7 and HPV18 E6/E7. In the BVAC-C-P1 phase I/IIa trial (NCT02866006), although the vaccine was safe, only one out of 26 patients (3.8%) achieved complete response, while 4 patients (15.4%) exhibited partial response94. The subsequent trial for BVAC-C (phase II, NCT04800978) is classified as “unknown status”. Two HPV16/18 E7-pulsed DC-based vaccines were developed by the Universities of Arkansas, USA, and Jena, Germany, respectively, and tested in HPV16/18+ cervical cancer patients, though no objective response was obtained for either of the studies95,96. A variant of the E7-pulsed DC vaccine from the University of Arkansas, containing keyhole limpet hemocyanin (KLH) instead of IL-2, was tested in a phase I trial on cervical cancer patients, where it was found to be safe and immunogenic97. Another autologous monocyte-derived DC-based vaccine was developed by the National Taiwan University Hospital and tested in a phase I trial on HPV16+ cervical cancer (NCT00155766), for which the completion status remains unknown. The trials for SQZ-eAPC-HPV and RTX-321 (both cell-based) were terminated, both because of corporate/sponsor decisions. Cell-based vaccines Furthermore, many cell-based vaccines were tested. The BVAC-C vaccine is based on autologous B cells and monocytes loaded with α-galactosyl ceramide and transduced with HPV16 E6/E7 and HPV18 E6/E7. In the BVAC-C-P1 phase I/IIa trial (NCT02866006), although the vaccine was safe, only one out of 26 patients (3.8%) achieved complete response, while 4 patients (15.4%) exhibited partial response94. The subsequent trial for BVAC-C (phase II, NCT04800978) is classified as “unknown status”. Two HPV16/18 E7-pulsed DC-based vaccines were developed by the Universities of Arkansas, USA, and Jena, Germany, respectively, and tested in HPV16/18+ cervical cancer patients, though no objective response was obtained for either of the studies95,96. A variant of the E7-pulsed DC vaccine from the University of Arkansas, containing keyhole limpet hemocyanin (KLH) instead of IL-2, was tested in a phase I trial on cervical cancer patients, where it was found to be safe and immunogenic97. Another autologous monocyte-derived DC-based vaccine was developed by the National Taiwan University Hospital and tested in a phase I trial on HPV16+ cervical cancer (NCT00155766), for which the completion status remains unknown. The trials for SQZ-eAPC-HPV and RTX-321 (both cell-based) were terminated, both because of corporate/sponsor decisions. Viral and bacterial vector vaccinesThe viral vector-based vaccine AD/MG1-E6E7 was tested in a phase Ib trial (NCT03618953) which was terminated due to issues with the vaccine vector. A phase I/II clinical trial (HPV001) for VTP-200 (an adenoviral vector-based vaccine specific for six early proteins of five hrHPV types), involving hr-HPV+ CIN1 patients, was recently completed, and an article is to be released soon (10.1093/cid/ciaf658). However, the Barinthus HPV program was abandoned. The HB-200 vaccine (also called TheraT and Eseba-vec) uses two arenaviruses, namely lymphocytic choriomeningitis virus (LCMV) and pichinde virus (PICV), as vectors, and targets HPV16 E6/E7. HB-200 has been administered in a phase I/II trial in the context of HPV16+ recurrent/metastatic cancers together with the standard of care. Out of 42 patients, 14% experienced grade ≥3 AEs. The overall response rate among the 35 evaluable patients reached 43%, including 3 complete responses and 9 confirmed partial responses98. The developer, Hookipa Pharma, however, recently announced their intention to suspend their activities for financial reasons, and the HPV development program has so far not been taken up by another company. Due to this decision, another trial involving HB-200 for patients with recurrent/metastatic oropharyngeal cancer (NCT06513884) was withdrawn. A Modified Vaccinia Ankara virus-based approach, named MVA-E2, targeting bovine papillomavirus E2 protein, was also tested on CIN2/399 and intraurethral flat condyloma100 patients. As this vaccine does not target human, but bovine papillomavirus, we chose not to include it as HPV vaccine in this review. Besides, no further mention of this approach has been published recently.Lastly, several vaccines based on bacterial vectors were tested in clinical trials, although their development was subsequently stopped. The Listeria monocytogenes-based vaccine ADXS11-001, targeting HPV16 E7, was tested in several trials on HPV16+ cervical cancer, CIN2/3, oropharyngeal cancer, and anal cancer patients. In most of these trials, patients experienced severe adverse events and dose-limiting toxicity. For instance, in the NCT01266460 phase II trial on cervical cancer patients, all of the 50 treated patients experienced AEs, among which 42% were grade 3 or 4. Only one patient had a complete response and two achieved partial response101. This vaccine also entered a phase III trial (NCT02853604) in cervical cancer, but the trial was terminated as none of the 110 patients survived the trial due to disease progression. The NCT01598792 phase I trial on oropharyngeal cancer patients was terminated because a patient suffered dose-limiting toxicity. Both BLS_ILB_E710c and GLBL101c target HPV16 E7 and are based on Lactobacillus casei. Both were tested in HPV16+ CIN3 patients. In the phase I/II trial for BLS_ILB_E710c, no grade 3 or higher AEs were recorded, and 75% of patients experienced clinical efficacy in the phase II part102. However, the absence of a control arm makes it difficult to discriminate the effect of the vaccine from spontaneous regression cases. GLBL101c was well tolerated, with no patients experiencing any serious AEs. 70% of the 10 patients treated with the optimal dose experienced a disease regression to CIN2 at week 9. 5 patients further regressed to LSIL or normal cytology 12 months after the vaccination. However, no follow-up studies were published since 2014103. Viral and bacterial vector vaccines The viral vector-based vaccine AD/MG1-E6E7 was tested in a phase Ib trial (NCT03618953) which was terminated due to issues with the vaccine vector. A phase I/II clinical trial (HPV001) for VTP-200 (an adenoviral vector-based vaccine specific for six early proteins of five hrHPV types), involving hr-HPV+ CIN1 patients, was recently completed, and an article is to be released soon (10.1093/cid/ciaf658). However, the Barinthus HPV program was abandoned. The HB-200 vaccine (also called TheraT and Eseba-vec) uses two arenaviruses, namely lymphocytic choriomeningitis virus (LCMV) and pichinde virus (PICV), as vectors, and targets HPV16 E6/E7. HB-200 has been administered in a phase I/II trial in the context of HPV16+ recurrent/metastatic cancers together with the standard of care. Out of 42 patients, 14% experienced grade ≥3 AEs. The overall response rate among the 35 evaluable patients reached 43%, including 3 complete responses and 9 confirmed partial responses98. The developer, Hookipa Pharma, however, recently announced their intention to suspend their activities for financial reasons, and the HPV development program has so far not been taken up by another company. Due to this decision, another trial involving HB-200 for patients with recurrent/metastatic oropharyngeal cancer (NCT06513884) was withdrawn. A Modified Vaccinia Ankara virus-based approach, named MVA-E2, targeting bovine papillomavirus E2 protein, was also tested on CIN2/399 and intraurethral flat condyloma100 patients. As this vaccine does not target human, but bovine papillomavirus, we chose not to include it as HPV vaccine in this review. Besides, no further mention of this approach has been published recently. Lastly, several vaccines based on bacterial vectors were tested in clinical trials, although their development was subsequently stopped. The Listeria monocytogenes-based vaccine ADXS11-001, targeting HPV16 E7, was tested in several trials on HPV16+ cervical cancer, CIN2/3, oropharyngeal cancer, and anal cancer patients. In most of these trials, patients experienced severe adverse events and dose-limiting toxicity. For instance, in the NCT01266460 phase II trial on cervical cancer patients, all of the 50 treated patients experienced AEs, among which 42% were grade 3 or 4. Only one patient had a complete response and two achieved partial response101. This vaccine also entered a phase III trial (NCT02853604) in cervical cancer, but the trial was terminated as none of the 110 patients survived the trial due to disease progression. The NCT01598792 phase I trial on oropharyngeal cancer patients was terminated because a patient suffered dose-limiting toxicity. Both BLS_ILB_E710c and GLBL101c target HPV16 E7 and are based on Lactobacillus casei. Both were tested in HPV16+ CIN3 patients. In the phase I/II trial for BLS_ILB_E710c, no grade 3 or higher AEs were recorded, and 75% of patients experienced clinical efficacy in the phase II part102. However, the absence of a control arm makes it difficult to discriminate the effect of the vaccine from spontaneous regression cases. GLBL101c was well tolerated, with no patients experiencing any serious AEs. 70% of the 10 patients treated with the optimal dose experienced a disease regression to CIN2 at week 9. 5 patients further regressed to LSIL or normal cytology 12 months after the vaccination. However, no follow-up studies were published since 2014103. Table 4Therapeutic HPV vaccines no longer pursuedVaccine nameVaccine typeDeveloperVaccine compositionClinical trialsHPV type and protein/peptide targetedAdjuvant/delivery systemIndicationTrial phaseAcronym/Identifier/Ref.ZYC101a/ AmolimogeneDNAEisai/MGI Pharma BiologicsHPV16 E6/E7 & HPV18 E6/E7poly (D,L-lactide-co-glycolide) microparticlesCIN2/3II/IIIZYC1-004(NCT00264732)HPV16 E6/E7 tattoo vaccineDNANetherlands Cancer InstituteHPV16 E6/E7Epitopes of HIV negative factor protein, P30 epitope from tetanus toxin, pan HLA-DRHPV16+ VIN2/3I/IINTR460781SGN-00101/HspE7ProteinAkela PharmaHPV16 E7Hsp65RRPIISGN-00101-0005(NCT00038714)HIV+ AIN2/3I/IINCI-2012-02507(NCT00052897)82CIN2/3IINCI-3074(NCT00060099)CIN3IINCI-5850(NCT00075569)83HPV16+ CIN3IINCI-2012-02513(NCT00054041)HPV16+ CIN1IINCI-2012-02623(NCT00091130)CIN1-3IHspE7-00101-0601(NCT00493545)GTL001/ProCervixProteinGenticelHPV16 E7 & HPV18 E7CyaAHPV16/18+ normal cytology and CIN1IPC10VAC05(NCT02689726)HPV16/18+ normal cytology and CIN1IIRHEIA-VAC(NCT01957878)84HPV-16 E6E7 ISCOMATRIXProteinUniv. of QueenslandHPV16 E6/E7ISCOMATRIXhrHPV+ HIV+ AIN1-3Ib86CIN1-3I87PD-E7ProteinUniv. of BrusselsHPV16 E7AS02B (Haemophilius influenzae protein D)hrHPV+ CIN1 &HPV16+ CIN3I/II88L1E7 CVLPProteinUniv. of JenaHPV16 E7 & L1Chimeric L1-based virus-like particles (CVLPs)CIN2/3I89Hespecta/ISA201Synthetic long peptidesISA PharmaceuticalsHPV16 E671-95& E6127-158Amplivant (TLR2 ligand)HPV16+ (pre)malignant lesionsI2014-000658-12(NCT02821494)90Treated HPV16+ OSCC patientsINL-OMON41192CIGB-228Short peptideCIGBHPV16 E786-93VSSPHPV16+ CIN2/391DPX-E7Short peptideDana-Farber/ ImmunovaccineHPV16 E711-19, HLA-A2-restrictedOil-based DepoVax (DPX) platformHPV16+ recurrent/ metastatic OPSCC, cervical or anal cancerI/II15-578 (NCT02865135)92PCI-E7Synthetic long peptidesPCI BiotechHPV16 E71-35 & E762-98Fimaporfin; poly-ICLCHealthy volunteersINCT0294785493BVAC-CCell-basedCellidHPV16 E6/E7 & HPV18 E6/E7Autologous B cells and monocytes loaded with α-galactosyl ceramideHPV16/18+ cervical cancerIIESR-18-14325(NCT04800978)HPV16/18+ cervical cancerI/IIBVAC-C-P1(NCT02866006)94E7-pulsed DCsCell-basedUniv. of JenaHPV16 E7 & HPV18 E7Autologous monocyte-derived DCsHPV16/18+ cervical cancer95E7-pulsed DCsCell-basedUniv. of ArkansasHPV16 E7 & HPV18 E7Autologous monocyte-derived DCs; IL-2HPV16/18+ cervical cancer96Autologous monocyte-derived DCs; KLHHPV16/18+ cervical cancerI97DC vaccineCell-basedNational Taiwan University HospitalHPV16 E7 peptidesAutologous PBMC-derived DCsHPV16+ cervical cancerINCT00155766SQZ-eAPC-HPVCell-basedSQZ BiotechnologiesHPV16 E6/E7Autologous PBMCs treated with CD86-, IL-2- and IL-12-encoding mRNAsHPV16+ solid tumorsI/IICOMMANDER-001(NCT05357898)RTX-321Cell-basedRubius TherapeuticsHPV16 E7-derivedHLA-A*02:01-binding peptideEngineered red blood cells expressing 4-1BBL and IL-12HLA-A*02:01+ HPV16+ solid tumorsINCT04672980AD/MG1-E6E7Viral vectorTurnstone BiologicsHPV16 E6/E7 & HPV18 E6/E7MG1 virus and AdenovirusHPV+ solid tumorsIAd-MG1-E6E7-002(NCT03618953)VTP-200Viral vectorVaccitech/Barinthus6 early proteins from 5 hrHPVsChimpanzee Adenovirus (ChAdOx) prime, MVA boosthrHPV+ CIN1I/IIHPV001(NCT04607850)HB-200(HB-201 + HB-202)/Eseba-vec/ TheraT/Viral vectorHookipa PharmaHPV16 E6/E7Lymphocytic choriomeningitis virus (LCMV) and Pichinde virus (PICV)HPV16+ recurrent/ metastatic cancerI/IIH-200-001(NCT04180215)98HPV16+ OPSCCI/IIIRB21-1031(NCT05108870)HPV16+ PD-L1+ recurrent/ metastatic OPSCCII/IIIH-200-004(NCT06513884)ADXS11-001/ Lovaxin C/Lm-LLO-E7Bacterial vectorAdvaxisHPV16 E7Listeria monocytogenes; LLOCIN2/3IILm-LLO-E7-07(NCT01116245)Cervical cancerIINCI-2011-02671(NCT01266460)101HPV16+ OPSCCI2010-019916-20(NCT01598792)Anal cancerI/IIBrUOG 276(NCT01671488)HPV16+ OPSCCIIH-36001 GCO 13-1411(NCT02002182)Cervical cancerILm-LLO-E7-1401(NCT02164461)Cervical cancer or HPV16+ OPSCCI/IIADXS001-04(NCT02291055)Cervical cancerIIIADXS001-02(NCT02853604)Anal cancerIIADXS001-06(NCT02399813)HPV16+ CIN3I/IIUMT2013-BLS-ILB-E710c(NCT02195089)102BLS_ILB_E710cBacterial vectorBioLeadersHPV16 E7Lactobacillus caseiHPV16+ CIN3I/IIa103GLBL101cBacterial vectorGENOLAC BLHPV16 E7Lactobacillus caseiHsp65 Heat shock protein 65, CyaA detoxified adenylate cyclase from Bordetella pertussis, VSSP very small size proteoliposomes, poly-ICLC polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose, KLH Keyhole Limpet Hemocyanin, LLO Listeriolysin O. Therapeutic HPV vaccines no longer pursued ZYC1-004 (NCT00264732) SGN-00101-0005 (NCT00038714) NCI-2012-02507 (NCT00052897)82 NCI-3074 (NCT00060099) NCI-5850 (NCT00075569)83 NCI-2012-02513 (NCT00054041) NCI-2012-02623 (NCT00091130) HspE7-00101-0601 (NCT00493545) PC10VAC05 (NCT02689726) RHEIA-VAC (NCT01957878)84 hrHPV+ CIN1 & HPV16+ CIN3 HPV16 E671-95 & E6127-158 2014-000658-12 (NCT02821494)90 ESR-18-14325 (NCT04800978) BVAC-C-P1 (NCT02866006)94 COMMANDER-001 (NCT05357898) HPV16 E7-derived HLA-A*02:01-binding peptide Ad-MG1-E6E7-002 (NCT03618953) HPV001 (NCT04607850) HB-200 (HB-201 + HB-202)/Eseba-vec/ TheraT/ H-200-001 (NCT04180215)98 IRB21-1031 (NCT05108870) H-200-004 (NCT06513884) ADXS11-001/ Lovaxin C/ Lm-LLO-E7 Lm-LLO-E7-07 (NCT01116245) NCI-2011-02671 (NCT01266460)101 2010-019916-20 (NCT01598792) BrUOG 276 (NCT01671488) H-36001 GCO 13-1411 (NCT02002182) Lm-LLO-E7-1401 (NCT02164461) ADXS001-04 (NCT02291055) ADXS001-02 (NCT02853604) ADXS001-06 (NCT02399813) UMT2013-BLS-ILB-E710c (NCT02195089)102 Hsp65 Heat shock protein 65, CyaA detoxified adenylate cyclase from Bordetella pertussis, VSSP very small size proteoliposomes, poly-ICLC polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose, KLH Keyhole Limpet Hemocyanin, LLO Listeriolysin O. Preclinical studies The importance of the choice of in vivo model While the vaccines highlighted in the previous sections already entered the clinical trial phase, many more vaccines are currently in the preclinical pipeline. Part of the reason why observed preclinical efficacy fails to translate into the clinical phase is believed to be the in vivo setting in which these vaccines were preclinically tested. Early models included rabbit-, dog- and cattle-specific papillomaviruses, leading to papillomata in their respective host species104. The first rodent papillomavirus model was Mastomys natalensis papillomavirus (MnPV) in the multimammate mouse Mastomys coucha105. Murine papillomavirus (MmuPV1) was detected in 2011106 and subsequently used as a model for papillomavirus infection in several mouse strains107. Other rodent papillomaviruses were subsequently isolated108. These animal papillomavirus models were very useful to get insights into the biology of papillomavirus infection and cancer development, and optimal timing of prophylactic or therapeutic intervention109. However, human papillomavirus vaccines cannot be assessed in these animal papillomavirus models. To allow in vivo testing of therapeutic HPV vaccines, the HPV oncogenes were introduced into murine cells, serving both as immortalization factors as well as antigenic targets. In this setting, subcutaneous tumors were cured numerous times, yet their location and tumor microenvironment do not match those of a mucosal tumor, which is the natural site for all HPV-induced lesions. On the contrary, orthotopic models, i.e., in which the tumor develops at the correct anatomical site, are more likely to display a similar response as human patients. Further, subcutaneous and orthotopic tumors display distinct immune cell accessibility and dynamics, as was shown in a study comparing two models obtained by injecting the same murine HNSCC cell line either subcutaneously or orthotopically110. One of the most common orthotopic models used for HPV-driven cancers is the TC-1 cell line111, either applied intravaginally or injected into organs of the oral cavity112,113. TC-1 cells originated from lung cells of C57BL/6 mice and were transduced to express HPV16 E6 and E7, as well as a mutated hRas in order to be tumorigenic111. Luciferase was later added to make the cells detectable in vivo112. Another orthotopic model was developed to mirror oropharyngeal tumors, namely AT84-E7. To this end, oral squamous cell carcinoma AT-84 cells, derived from C3H mice, were genetically modified to stably express HPV16 E7 and luciferase114. Still, these models display only murine MHC molecules and are thus not suited to analyze HLA-restricted (i.e. human) immune responses. In particular, mice carrying the H2-Db MHC molecule (C57BL/6 strain) strongly react to an immunodominant E7 epitope, namely E749-57, which cannot bind most human HLA molecules115. The presence of one highly immunodominant epitope does not reflect the situation in the outbred human population. Therefore, results obtained in such murine models are not predictive for clinical success. Results from mouse strains that express human or humanized MHC molecules are more likely to translate into the clinic. Some vaccines from the pNGVL4a vaccine family were tested in HLA-A2 transgenic mice, in which the human HLA-A2 molecule was knocked-in in addition to murine MHCs116. This approach, however, still faces the challenge of the immunodominant E7 epitope being presented. More suitable are mouse strains such as A2.DR1, which are knocked-out for murine MHC and knocked-in for human HLA-DR1 and humanized MHCI (HLA-A2)117, or ABab-I mice, which were knocked-in for 7 HLA class I alleles118. Indeed, our group developed two in vivo models for the A2.DR1 mouse strain, first a syngeneic sarcoma-based model carrying the HPV16 oncogenes merely as antigenic targets119, and subsequently an HPV oncogene-dependent tumor model, mirroring the development of TC-1, named E6/7-lucA2120,121. The latter model is the first to combine HLA expression and orthotopic localization (intravaginal and oropharyngeal). In the following section, we highlight selected preclinical studies that seem promising, in particular in regard to the in vivo model used or the robustness of the results obtained. We feature studies performed in orthotopic models, as well as in HLA-humanized mice, and using some novel and promising vaccine formulations (Table 5).Table 5Selection of promising preclinical vaccine candidatesVaccine descriptionModel system descriptionResultsRef.HPV type and protein/peptide targetedVaccine compositionMouse strainTumor cell lineTumor locationHPV16 E7gDE7: mRNA encoding HPV16 E7 fused to HSV-1gD, encapsulated in LNPsC57BL/6HPV16 E6+/E7+ TC-1-lucVaginal & oralSystemic HPV16-specific immune response and complete regression of ivag. and oral tumors.122HPV16 E6/E7 & HPV18 E6/E7mHTV: mRNA encoding HPV16/18 E6/E7, encapsulated in LNPsC57BL/6HPV16 E6+/E7+ TC-1-lucVaginalLimited tumor growth, leading to a better survival compared to PBS and an irrelevant mRNA vaccine and protective effects upon s.c. re-challenge.Increased IFNγ secretion by ELISpot in response to HPV16/18 E6/E7 challenge in non-human primates 4 weeks after immunization.123HPV16 E744-62HPV peptide and Q11 peptide connected by covalent bonding, self-assembling into nanofibersC57BL/6HPV16 E6+/E7+ TC-1-lucVaginalVaccination via s.c., i.n. and ivag. route induced systemic HPV16-specific immune response and ivag. tumor size reduction.124HPV16 E7 & HPV18 E7hEDA-HPVE7-16/18: Fusion protein consisting of HPV16 E7, HPV18 E7 and human fibronectin EDA (TLR4 agonist) + poly ICLCC57BL/6HPV16 E6+/E7+ TC-1-lucVaginalVaccination induced systemic HPV16/18-specific immune response and suppression of ivag. tumor growth in 100% of mice.125HPV16 E7αDEC205-E7: Anti-DEC205 monoclonal antibody fused to E7 + poly(I:C)C57BL/6HPV16 E6+/E7+ TC-1-lucVaginal & oralOverall survival in vaginal setting (day 60): significantly higher in the fully treated group vs the poly-IC alone group and untreated group.Overall survival in oral setting (day 120): significantly higher in the fully treated group vs the poly-IC alone group.126HPV16 E7Cationic nanosized hydrogel particle (cCHP nanogel) containing HPV16 E7, adjuvanted by cyclic di–adenosine monophosphateC57BL/6HPV16 E6+/E7+ TC-1-lucVaginalComplete inhibition of tumor growth in the vaccinated group, which was significantly higher than the unimmunized and empty nanogel groups.Significantly increased IFNγ secretion by ELISpot in response to HPV16 E7 challenge in non-human primates 11 weeks after immunization.127HPV16 E711-19Silica nanoparticles loaded with HPV16 E711-19 and poly(I:C)A2.DR1HPV16 E6+/E7+ PAP-A2s.c.Complete tumor regression in 5/9 mice, which was significantly higher than for mice treated with PBS or empty SiNPs with poly-IC.128HPV16 E6/E7 & HPV18 E6/E7P016-2: N1-methylpseudouridine-containing mRNA encoding HPV16/18 E6/E7, encapsulated in LNPsC57BL/6HPV16 E6+/E7+ TC-1 & HPV18 E6+/E7+ MC38s.c.Significantly improved animal survival, especially when combined with anti-PD1 checkpoint inhibitor.129HPV16 E7mRNA encoding HPV16 E7 encapsulated in LNPsC57BL/6HPV16 E6+/E7+ TC-1s.c.Significantly improved animal survival and reduced tumor growth compared to LNP control and induced strong specific cytotoxic response.130HPV16 E749-57LNP(E7Ag-E10/IMDQ-E10): LNPs containing E749-57 peptide linked to an anionic glutamic acid decamer (E10) and imidazoquinolineC57BL/6HPV16 E6+/E7+ TC-1s.c.100% efficacy at day 20 in both prophylactic and therapeutic settings.131HPV16 E6/E7T22H07: Oncolytic herpes simplex virus 1 (oHSV-1) expressing E6/E7 fusion proteinM22H04: LNP-enveloped mRNA expressing tHA-mE7-mE6C57BL/6HPV16 E6+/E7+ TC-1s.c.Complete regression (day 35): 80% for combination treatment, max. 40% for single treatments.The combination of both vaccines induced significantly more specific CD8+ T cells than either vaccine alone.132LNP Lipid nanoparticles. Table 5Selection of promising preclinical vaccine candidatesVaccine descriptionModel system descriptionResultsRef.HPV type and protein/peptide targetedVaccine compositionMouse strainTumor cell lineTumor locationHPV16 E7gDE7: mRNA encoding HPV16 E7 fused to HSV-1gD, encapsulated in LNPsC57BL/6HPV16 E6+/E7+ TC-1-lucVaginal & oralSystemic HPV16-specific immune response and complete regression of ivag. and oral tumors.122HPV16 E6/E7 & HPV18 E6/E7mHTV: mRNA encoding HPV16/18 E6/E7, encapsulated in LNPsC57BL/6HPV16 E6+/E7+ TC-1-lucVaginalLimited tumor growth, leading to a better survival compared to PBS and an irrelevant mRNA vaccine and protective effects upon s.c. re-challenge.Increased IFNγ secretion by ELISpot in response to HPV16/18 E6/E7 challenge in non-human primates 4 weeks after immunization.123HPV16 E744-62HPV peptide and Q11 peptide connected by covalent bonding, self-assembling into nanofibersC57BL/6HPV16 E6+/E7+ TC-1-lucVaginalVaccination via s.c., i.n. and ivag. route induced systemic HPV16-specific immune response and ivag. tumor size reduction.124HPV16 E7 & HPV18 E7hEDA-HPVE7-16/18: Fusion protein consisting of HPV16 E7, HPV18 E7 and human fibronectin EDA (TLR4 agonist) + poly ICLCC57BL/6HPV16 E6+/E7+ TC-1-lucVaginalVaccination induced systemic HPV16/18-specific immune response and suppression of ivag. tumor growth in 100% of mice.125HPV16 E7αDEC205-E7: Anti-DEC205 monoclonal antibody fused to E7 + poly(I:C)C57BL/6HPV16 E6+/E7+ TC-1-lucVaginal & oralOverall survival in vaginal setting (day 60): significantly higher in the fully treated group vs the poly-IC alone group and untreated group.Overall survival in oral setting (day 120): significantly higher in the fully treated group vs the poly-IC alone group.126HPV16 E7Cationic nanosized hydrogel particle (cCHP nanogel) containing HPV16 E7, adjuvanted by cyclic di–adenosine monophosphateC57BL/6HPV16 E6+/E7+ TC-1-lucVaginalComplete inhibition of tumor growth in the vaccinated group, which was significantly higher than the unimmunized and empty nanogel groups.Significantly increased IFNγ secretion by ELISpot in response to HPV16 E7 challenge in non-human primates 11 weeks after immunization.127HPV16 E711-19Silica nanoparticles loaded with HPV16 E711-19 and poly(I:C)A2.DR1HPV16 E6+/E7+ PAP-A2s.c.Complete tumor regression in 5/9 mice, which was significantly higher than for mice treated with PBS or empty SiNPs with poly-IC.128HPV16 E6/E7 & HPV18 E6/E7P016-2: N1-methylpseudouridine-containing mRNA encoding HPV16/18 E6/E7, encapsulated in LNPsC57BL/6HPV16 E6+/E7+ TC-1 & HPV18 E6+/E7+ MC38s.c.Significantly improved animal survival, especially when combined with anti-PD1 checkpoint inhibitor.129HPV16 E7mRNA encoding HPV16 E7 encapsulated in LNPsC57BL/6HPV16 E6+/E7+ TC-1s.c.Significantly improved animal survival and reduced tumor growth compared to LNP control and induced strong specific cytotoxic response.130HPV16 E749-57LNP(E7Ag-E10/IMDQ-E10): LNPs containing E749-57 peptide linked to an anionic glutamic acid decamer (E10) and imidazoquinolineC57BL/6HPV16 E6+/E7+ TC-1s.c.100% efficacy at day 20 in both prophylactic and therapeutic settings.131HPV16 E6/E7T22H07: Oncolytic herpes simplex virus 1 (oHSV-1) expressing E6/E7 fusion proteinM22H04: LNP-enveloped mRNA expressing tHA-mE7-mE6C57BL/6HPV16 E6+/E7+ TC-1s.c.Complete regression (day 35): 80% for combination treatment, max. 40% for single treatments.The combination of both vaccines induced significantly more specific CD8+ T cells than either vaccine alone.132LNP Lipid nanoparticles. Selection of promising preclinical vaccine candidates Limited tumor growth, leading to a better survival compared to PBS and an irrelevant mRNA vaccine and protective effects upon s.c. re-challenge. Increased IFNγ secretion by ELISpot in response to HPV16/18 E6/E7 challenge in non-human primates 4 weeks after immunization. Overall survival in vaginal setting (day 60): significantly higher in the fully treated group vs the poly-IC alone group and untreated group. Overall survival in oral setting (day 120): significantly higher in the fully treated group vs the poly-IC alone group. Complete inhibition of tumor growth in the vaccinated group, which was significantly higher than the unimmunized and empty nanogel groups. Significantly increased IFNγ secretion by ELISpot in response to HPV16 E7 challenge in non-human primates 11 weeks after immunization. T22H07: Oncolytic herpes simplex virus 1 (oHSV-1) expressing E6/E7 fusion protein M22H04: LNP-enveloped mRNA expressing tHA-mE7-mE6 Complete regression (day 35): 80% for combination treatment, max. 40% for single treatments. The combination of both vaccines induced significantly more specific CD8+ T cells than either vaccine alone. LNP Lipid nanoparticles. Studies in orthotopic models Ramos da Silva and colleagues studied the effect of their mRNA-based lipid nanoparticle (LNP) vaccine (gDE7) in TC-1 orthotopic intravaginal and sublingual tumors122. The vaccine consisted of an mRNA encoding for HPV16 E7 fused with the herpes simplex virus type I glycoprotein D. Several versions of the vaccine were tested (non-replicating or self-amplifying mRNA, with or without nucleoside modification), reaching complete tumor regression with two vaccine formulations in both orthotopic settings. Lee et al. also tested an mRNA-based vaccine in the orthotopic setting. There, the HPV16/18 E6/E7-targeted vaccine (mHTV) was tested in an intravaginal TC-1 tumor model123. mHTV was able to limit the tumor growth in mice, leading to a better survival compared to PBS and an irrelevant mRNA vaccine. Further, mHTV exhibited protective effects in mice re-challenged with TC-1 subcutaneously. Finally, the immunogenicity of mHTV was also tested and validated in non-human primates, whose PBMCs exhibited increased IFNγ secretion 4 weeks after immunization by ELISpot in response to HPV16/18 E6/E7 challenge. A similar vaccine based on this platform is currently entering the clinical trial phase for the treatment of precursor lesions, with the name RG002. Several studies tested promising peptide- or protein-based vaccines in orthotopic settings. The long peptide HPV16 E744-62 was fused to Q11, a self-assembling peptide, and administered both subcutaneously and locally in the mucosa in genital TC-1 tumors124. The intravaginal route was most effective in limiting tumor growth and most potent in eliciting immune responses. Another study combined HPV16 and HPV18 E7 and the TLR4 agonist human fibronectin extra domain A (EDA) in a fusion protein, administered together with poly-ICLC, a derivative of the TLR3 agonist poly-IC125. This vaccine, named hEDA-HPVE7-16/18, was tested on TC-1 genital tumors, where it induced a significant IFNγ response after 7 days. A boost vaccine was administered 7 days after the first vaccination, leading to an overall survival of 100% at day 68, while the unvaccinated group exhibited 20% survival. An additional study led by Silva et al. investigated the effect of αDEC205-E7 mAb on vaginal and oral TC-1 tumors126. The vaccine, composed of an anti-DEC205 monoclonal antibody (targeting a DC C-type lectin receptor) fused to HPV16 E7, was associated with poly-IC. The treatment resulted in an overall survival of 80% in the vaginal setting at day 60, while the poly-IC alone group reached 40% survival and the non-treated mice had to be sacrificed by day 30. For the tongue tumors, the vaccine showed 100% efficacy, which was not significantly different from the poly-IC alone treatment group (75% survival). However, the vaccine allowed mice to survive to a tumor re-challenge, which was not the case for poly-IC alone. Finally, a recently published study developed a cationic nanosized hydrogel particle containing the E7 protein (cCHP-nanogel-E7) and adjuvanted with cyclic di-adenosine monophosphate. The vaccine was tested in intravaginal TC-1-luc tumors and showed a complete inhibition of tumor growth in comparison with unimmunized mice and mice immunized only with the nanogel vector. Additionally, non-human primates were immunized with the vaccine and developed a strong specific T cell response shown by ELISpot and flow cytometry127. Studies in subcutaneous models While the orthotopic setting better reflects the tumor microenvironment of the patients and is therefore better suited for preclinical testing, several promising vaccines have been tested subcutaneously. A silica nanoparticle (SiNP) peptide-based vaccine targeting HPV16 E711-19 in association with poly-IC128 was tested against s.c. tumors in an MHC-humanized mouse model. This vaccine was tested in HLA-humanized A2.DR1 mice, where it induced a vaccine-specific CD8+ T cell response. It was further tested on subcutaneous PAP-A2 tumors, a syngeneic HPV16 E6/E7+ tumor model for A2.DR1. The vaccine led to complete tumor regression in 5 out of 9 mice, which was significantly higher than for mice treated with PBS or empty SiNPs with poly-IC. A recent paper by Zhang et al. tested an mRNA construct targeting HPV16 and HPV18 E6 and E7 on subcutaneous tumors129. The vaccine, termed P016-2, was encapsulated in lipid nanoparticles (LNP) and additionally encoded the granulocyte-macrophage colony-stimulating factor (GM-CSF). It was tested on TC-1 (HPV16+) and MC38 (HPV18+) tumor models, where it significantly improved animal survival. Of note, the effect of the vaccine was strengthened by combination with an anti-PD-1 checkpoint inhibitor, allowing complete tumor control and reaching 100% survival at day 24 in the MC38 model (vs. 80% for the vaccine monotherapy). Peng et al. tested another mRNA construct, targeting HPV16 E7, which was also encapsulated in LNP130. This vaccine induced a potent CD8 T cell response as well as changes in the tumor microenvironment, such as a decrease in Ki67 expression, and was associated with an improved survival and decreased tumor weight. Ye and colleagues developed LNPs containing the HPV16 E749-57 peptide, linked to an anionic glutamic acid decamer (E10) and further including the TLR7/8 agonist imidazoquinoline131. The vaccine, termed LNP(E7Ag-E10/IMDQ-E10) demonstrated 100% efficacy at day 20 in both a prophylactic and a therapeutic setting against TC-1 tumors. Further, it was able to elicit a specific CD8 T cell response. Finally, other studies combined two vaccines. As an example, a study conducted by Zhang et al. used a combination of T22H07, an oncolytic herpes simplex virus engineered to express an HPV16 E6/E7 fusion protein, and M22H04, an LNP-enveloped mRNA composed of HPV16 E6 and E7 sequences fused with haemagglutinin protein132. The two vaccines synergized and led to 80% complete regression 35 days after s.c. TC-1 implantation, while either vaccine alone reached 40% complete regression or less. The combination of both vaccines additionally induced significantly more specific CD8+ T cells than either vaccine alone. The growing role of in silico analyses in vaccine design Recent developments in therapeutic vaccine design have highlighted the growing use of in silico tools to predict the safety and efficacy of future vaccines. Also in the HPV therapeutic vaccine field, many studies have started to adopt an in silico workflow for vaccine design133–136. This workflow typically starts by the identification of cytotoxic T lymphocyte (CTL) epitopes using the Immune Epitope Database (IEDB) and the NetMHCpan tool. Sometimes, additionally, helper T lymphocyte and B lymphocyte epitopes are also identified using IEDB, NetMHCIIpan and ABCpred or Bepipred. The antigenicity of the epitopes (and of the vaccine construct) can be predicted by using tools such as VaxiJen, and their ability to induce a cytokine response with servers such as IFNepitope, IL10pred or IL4pred. IEDB also offers tools to estimate the population coverage of the epitopes. Further, the allergenicity of the epitopes (and vaccine construct) can be assessed with servers such as AllergenFP or AllerTOP, while the toxicity can be predicted with the ToxinPred server. The physiochemical properties of the vaccine can be determined via the ProtParam tool. To predict efficient processing of the vaccine, an analysis with TAPPred can be run, in silico analyzing the vaccine affinity towards TAP molecules. In a next step, the secondary and tertiary structures of the vaccine can be determined using among others PSIPRED (secondary structure) and AlphaFold (tertiary structure). The most recent version of AlphaFold, namely AlphaFold3, was released recently137. The tertiary structure often requires to be visualized by another software (such as PyMOL) and refined (for instance using Galaxy-Refine). Subsequently, other parameters can be predicted, such as the vaccine affinity for TLRs (using ClusPro), its molecular dynamics (for instance with iMOLs) and immunogenicity (using C-ImmSim). A more complete review of the different tools available was recently published by Najafi et al.138. The advent of these machine learning/artificial intelligence (AI) tools allows to address previous common challenges in vaccine design, by processing and integrating bigger datasets, while accelerating the process. However, one must keep in mind that these analyses remain predictions, and thus need to be interpreted with caution and verified experimentally. For instance, immunogenicity assays are required to verify that the selected epitopes are indeed potent in inducing an immune response, and the different immune cells predicted to be triggered by the vaccine need to be experimentally verified as well. Furthermore, AI tools still need to be improved in terms of interpretability, transparency, reliability and robustness. The two latter aspects highly depend on the heterogeneity and availability of training data, another factor remaining to be harmonized139. With the rapid advances in AI technology, it is to be expected that in silico analyses will play an increasing role in the vaccine development pipeline. Discussion In the rapidly evolving field of tumor immunotherapy, therapeutic cancer vaccines constitute a promising avenue due to their specificity and low side effects. However, therapeutic cancer vaccines often require to first identify tumor-specific or tumor-associated antigens. HPV therapeutic vaccines do not present this challenge, as all tumor cells have by definition been infected by HPV and present immunologically foreign HPV epitopes at their cell surface that are not expressed on healthy cells. For this reason, HPV therapeutic vaccination has been intensively researched, with some vaccines already reaching phase III trials, and continues to evolve today. As therapeutic options currently already exist for both precursor lesions and HPV-driven cancers, it is important that therapeutic vaccines (including combination treatments) reach at least the same efficacy as the current standard of care for them to be approved. Furthermore, in particular at the precursor lesion stage, spontaneous regression is not a rare phenomenon. Besides, as every clinical trial design is different, it can be very difficult to compare one study to another. Therefore, clinical efficacy trials should include control arms to know whether the effect observed in the treatment arm could be due to spontaneous regression, and if the efficacy could reach that of a standard of care treatment. It has also been observed that some control arms behaved very differently between the phase II and phase III trials of a same vaccine, further stressing the need for including a control arm at each step of the development process. A reason for this is that multiple factors, such as age of the patient or HPV type, can influence the response to treatment and/or the spontaneous regression of a lesion. For this reason, it is necessary that the control arm is as closely matched as possible to the treated group when assessing a new HPV therapeutic vaccine. Because all trials are designed differently (control arm inclusion, HPV-type restriction, type of lesion/cancer treated, combination with other treatment modalities, etc.), it is extremely difficult to compare studies. Furthermore, meta-analyses are hampered by the fact that not all the studies and trials are recorded on clinicaltrials.gov or other databases, making it extremely difficult to get a complete overview of all the ongoing research. Besides, even if the studies are recorded, the results are not always added to the database, strengthening this effect even more. Nonetheless, two meta-analyses of HPV therapeutic vaccine clinical trials have been performed140,141. Some of the approaches included in the meta-analyses are no longer actively followed and thus are listed in Table 4. We also only focused on vaccines targeting actual HPV-derived proteins, and therefore did not include vaccines such as MVA-E2, targeting bovine papillomavirus, or UCPVax, using Tert as a target protein. As an example for a meta-analysis, Alouini and Pichon published a systematic review141, where 843 records were identified, among which only 9 randomized controlled trials (RCTs) met the criteria to qualify for qualitative synthesis. 7 of these RCTs (677 participants) involved CIN2/3 and demonstrated lesion regression after treatment. However, 2 of these had a high-risk for bias and one did not include statistical analysis. As a result, four trials (598 participants) were analyzed40,52,142,143. Even so, a pooling of the p-values revealed a significant difference between vaccine and placebo groups. The 2 other RCTs focused on advanced cervical cancer, where the vaccine treatment did not show a significant difference in outcome144,145. Of note, these two studies were performed in the era before checkpoint blockade combination therapy. These results suggest that therapeutic HPV vaccination as a monotherapy would be more efficient at the stage of precursor lesions. This is corroborated by the biological mechanisms occurring at the different stages, with an immunosuppressing microenvironment being present already at the advanced precursor lesion stage (CIN3)34, while spontaneous regression can still occur in the case of precursor lesions. This also is in line with the WHO preferred product characteristics, which recommend to target precursor lesions17. However, many vaccine approaches that were unsuccessful in the precursor lesion setting are now being tried on advanced cancers, and some vaccines even were exclusively assessed in this setting. This can be explained by the fact that in the case of advanced diseases, therapeutic vaccines can be combined with other treatments, mainly immune checkpoint inhibitors (ICIs), and act synergistically. This is not possible in the intraepithelial neoplasia stage, as ICIs can have potentially lethal side effects. Secondly, this paradox can be explained by the difficulty to find investors to finance trials at the precursor lesion stage, since for this application, vaccines need to be better and as safe as the standard of care (typically consisting of conization or ablation). This is not the case for advanced cancers where the standard of care either has been already tried and failed, or will be associated with severe side effects in any case. Despite those challenges, it is surprising that no breakthrough in the field of HPV therapeutic vaccination has been achieved to date, even in precursor lesions, given the multitude of approaches that have been tried. One possible explanation for this could be the use of unsuitable murine models. Indeed, subcutaneous models do not accurately reflect the tumor immune microenvironment found in oral or anogenital tumors, which is better mirrored by orthotopic models. As such, a vaccine that is promising in a subcutaneous setting could fail to elicit a response in an orthotopic one. Further, most studies are performed on C57BL/6 mice, which exhibit the immunodominant HPV epitope E749-57. Therefore, vaccines eliciting immune responses against this epitope will obtain excellent results in these mice, but will not elicit any response in humans, where this epitope is not presented. For this reason, HLA-humanized mice represent a more accurate platform for testing new vaccine candidates. Additionally, the limited success encountered so far could be explained by the choice of vaccine vehicle, which might fail to elicit a cytotoxic T cell response. Another potential explanation for the limited success of therapeutic vaccines in precursor lesions could be that clinical trials on precursor lesions often include CIN3 patients, which, from an immune evasion point of view, resembles more the cancer stage. Studies on “true” precursor lesions, where the immune microenvironment is not yet immunosuppressive, should ideally be performed on infected healthy individuals or CIN1 patients. This implies that large studies would be needed to account for the amount of spontaneous regression. Altogether, the efficacy and translatability of therapeutic HPV vaccine approaches could be improved by implementing the following points: vaccines should be tested in appropriate murine models (i.e. with a truly orthotopic tumor setting and a human MHC expression system); precursor lesions should be targeted to follow the principle of cancer interception; and finally, every trial should include a control group matching the vaccine-treated group as closely as possible to discriminate spontaneous regression and showcase the effect of the tested vaccine. Recent advances have shown that biomarkers such as HPV methylation and p16/Ki67 dual stain positivity are predictors for an enhanced risk of disease progression. p16/Ki67 dual staining has now been FDA approved as a measure to sort positive patients for further examination146. This information could help in understanding the efficacy of new HPV therapeutic vaccines34. In particular, vaccination studies could be focused on these patients, and it would be useful to see if an increased portion of these patients are vaccine non-responders. In conclusion, while HPV therapeutic vaccines seem to have encountered modest success so far, promising approaches are currently being tested in clinical trials. Therapeutic vaccine monotherapy should be indicated for precursor lesions rather than for advanced cancer stages, while combination therapies are a viable possibility in cancer. Further approaches are being developed and tested preclinically. New animal models are being developed to meet the need to assess vaccine efficacy in the most clinically representative setting possible. Finally, in silico tools are now being integrated in the vaccine design pipeline, with the aim of developing more efficacious vaccine platforms.